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B                             C 
Abstract 
 
The ubiquitous second messenger 3',5'-cyclic adenosine monophosphate (cAMP) is a crucial 
regulator of cardiac function and disease. It is known that cAMP signaling is mediated by 
discrete functional microdomains each containing a specific subset of differentially localized 
receptors, protein kinases and specific phosphodiesterases (PDEs). Cardiac 
phosphodiesterases (PDE1-5; PDE8 and 9) hydrolyze cyclic nucleotides, each with different 
selectivity and affinity for their substrates cAMP and 3',5'-cyclic guanosine monophosphate 
(cGMP). In one of these microdomains, the phosphorylation of the FXYD1 protein called 
Phospholemman (PLM), the negative regulator of Na+/K+-ATPase (NKA),  via PKA or PKC 
leads to an increase of NKA activity and its sodium affinity, thereby lowering intracellular 
sodium levels and hence limiting cardiac inotropy. By obstructing high sodium levels during 
adrenergic stimulation it simultaneously favors calcium extrusion via the sodium-calcium 
exchanger (NCX). This mechanism may prevent calcium-overload, hypertrophy and triggered 
arrhythmias during cardiac stress. Interestingly, PLM expression is known to be altered in 
cardiomyocytes from postinfarcted rat hearts which results in depressed NKA activity. 
However, knowledge about the dynamics of cAMP pool coupled to PLM phosphorylation and 
the interactions of β-adrenergic receptors (β-AR) with individual cardiac PDE subtypes 
forming this important microdomain as well as their alterations in cardiac disease is 
insufficient. To investigate these questions, we developed a Förster Resonance Energy 
Transfer (FRET)-based PLM targeted cAMP biosensor PLM-E1. It can be used to precisely 
measure cAMP dynamics and to understand the regulatory mechanisms behind a possible 
local restriction of β-AR mediated cAMP signals in the PLM/NKA microdomain of adult rat 
ventricular myocytes (ARVMs).  
 
Using functional 86Rubidium-flux measurements in a PLM-E1 expressing stable HEK cell line, 
co-immunoprecipitation analysis of PLM-E1 transfected ARVMs and confocal microscopy, 
we showed that the newly developed PLM-E1 biosensor is associated with the α1 subunit 
(SU) of the NKA. The obtained FRET results were compared with measurements in the bulk 
cytosol performed using the cytosolic E1-camps sensor. It is well known that PDE2 activity 
constitutes a relatively low proportion of total cardiac PDE activity in the rat heart. However, 
our findings suggest that the actions of PDE2 regulate cAMP signals in the PLM 
microdomain in a compartmentalized manner at basal state (without prestimulation with β-AR 
agonists). Using the targeted FRET biosensor PLM-E1 in ARVMs we further analyzed the 
subtype specific β-AR control of cAMP in the PLM/NKA domain. Interestingly, the β2-AR 
showed a distinct control over the PLM microdomain during adrenergic stimulation. Local 
cAMP-FRET responses to PDE3 inhibition were well detectable in the PLM/NKA 





vicinity of PLM upon adrenergic stimulation. Focusing on β2-AR stimulated cAMP pools in the 
PLM/NKA microdomain, we observed alterations of FRET responses in ARVMs from animals 
with chronic heart failure induced by myocardial infarction. These failing cells showed a 
significant loss of the PDE3 responses upon β2-AR stimulation and an almost compensating 
increase in PDE2 dependent control of cAMP in the vicinity of PLM. Strikingly, in this disease 
model the overall response of β2-AR to adrenergic stimulation in the PLM microdomain was 
reduced to a level comparable to the bulk cytosol.  
 
In this study, the efficiency of the targeted PLM-E1 biosensor and its potential for real time 
monitoring of compartmentalized cAMP signaling in adult rat ventricular myocytes was 
successfully demonstrated. In addition, the practicability of the tagged biosensor in ARVMs in 
a cardiac disease model was confirmed and analyzed. In particular, our data show that real 
time dynamics of cAMP in the PLM/NKA microdomain are significantly different from 
cytosolic cAMP in terms of local PDE regulation and direct receptor-mediated control of the 
microdomain. In heart failure, these mechanisms are seriously altered which might explain 







1. 1 β-adrenergic signaling pathway 
 
1. 1. 1 Subtype specific β-adrenergic signaling in the heart 
 
As classic members of heptahelical G protein-coupled receptors (GPCRs), β-adrenergic 
receptors (β-ARs) are important mediators of sympathetic nervous system control. They are 
functionally involved in various processes such as metabolic regulation1, immune reactions2, 
growth control3, vascular smooth muscle cell contraction and relaxation4 as well as cell 
survival and apoptosis5. The textbook paradigm for β-AR signaling in the heart is the 
regulation of cardiac function via their activation by catecholamines; the sympathetic 
stimulation increases heart rate (positive chronotropic effect), myocardial contractility 
(positive inotropic effect) and accelerates relaxation (positive lusitropic effect)6. There are 
three different types of β-ARs expressed in the mammalian heart: β1-, β2- and β3-ARs. The 
β1-AR is found primarily in the heart and comprises 75-80% of the cardiac β-ARs
7. This 
receptor is coupled to stimulatory G-proteins (Gs) which in turn activate adenyl cyclase (AC), 
an enzyme responsible for the generation of the second messenger 3'-5'-cyclic adenosine 
monophosphate (cAMP) from ATP. Increasing cAMP levels activate cAMP-dependent 
protein kinase (PKA)8, cyclic nucleotide gated channels (CNGCs)9 and the exchange protein 
directly activated by cAMP (Epac)10,11 (Figure 1). The latter seems to have prohypertrophic 
effects upon chronic β1-AR stimulation, being a PKA independent downstream effector of 
sympathetic stimulation. Epac expression is increased in heart failure, where Epac activates 
Rap (a small GTPase) and induces hypertrophy in a cAMP-dependent but PKA-independent 
manner12. In the heart, cAMP signal transduction is mainly mediated through PKA with its two 
regulatory (R)- and two catalytic (C)-subunits8. When cardiac cAMP binds the R-subunits, the 
C-subunits dissociate from the R-subunits13, which leads to a phosphorylation of downstream 
targets critical for the regulation of excitation contraction coupling (ECC). During cardiac ECC 
downstream effector proteins such as troponin I, the L-type Ca2+ channel (LTCC), 
phospholamban (PLB)14 and phospholemman (PLM) as the inhibitory protein of the sodium 
potassium pump (NKA)15 serve as PKA substrates, resulting in greater contractility and acute 
cardiac performance thereby facilitating diastolic function of the heart.  
Contraction force is primarily controlled by sympathetic stimulation via β1-AR cAMP and 
elevated intracellular Ca2+ levels upon phosphorylation of voltage-gated LTCC, whereas the 
lusitropic effect of PKA is mediated by increased Ca2+ reuptake into the sarcoplasmic 
reticulum (SR) consequent to PLB phosphorylation and increased SERCA2a activity16. As an 
important part of the sympathetic 'fight or flight' response the NKA pump activity is 





Figure 1. Schematic representation of the cellular cAMP signaling cascade. After stimulation of a GPCR, 
cAMP production is accelerated via G protein dependent AC activation. cAMP has three different downstream 
effectors: PKA, Epac and CNGCs . The catalytic (C) subunits of the PKA dissociate from the regulatory (R) 
subunits and phosphorylate several downstream targets such as PLM, PLN, LTCC, Troponin I, RyR, PDEs 
and CREB. Epac and the small GTPases Rap, in response to cAMP, activate CaMKII through phospholipase 
Cε (PLCε) to regulate cardiac Ca
2+
 handling proteins. CNGCs show an increase in ion currents upon cAMP 
binding to these channels. 
 
response to elevated intracellular Na+ levels through the Ca2+ transient driven Na+ entry via 
the Na+/Ca2+ exchanger (NCX)17 (see section 1. 2. 1). Supported by several investigations 
about the effects of Ca2+/calmodulin-dependent protein kinase II (CaMKII) upon β-AR 
stimulation, there is a great possibility  that excessive β-AR stimulation is detrimental 
because of CaMKII mediated hyperphosphorylation of Ca2+ handling proteins (e.g. ryanodine 


















The β2-AR comprises 20–25% of cardiac β-ARs
7 and is expressed in several other tissues 
such as in the lung19 and kidney20. There is growing evidence for highly localized β2-AR 
dependent AC/cAMP/PKA signaling21. Previous studies in cardiac myocytes22-24 have shown 
an inotropic effect of β2-ARs mediated cAMP without having a direct influence on the 
phosphorylation status of PKA targets important for cardiac contraction, like PLB. It was 
suggested that β2-AR stimulation causes greater stimulation of the Gs-AC system and has a 
greater efficacy compared to the β1-AR
25-27. Not only for this reason, cardiac β2-AR mediated 
cAMP signal transduction has been described to be quantitatively and qualitatively different 
from β1-AR induced signals
28 and markedly altered in heart failure29. However, in addition to 
Gs, the β2-AR couples to pertussis toxin - sensitive inhibitory G protein (Gi) 
22.  
Cehn-Izu et al. suggested, that the local β2-AR signaling character is Gi dependent; the joint 
signaling of β2-AR to both Gs- and Gi-proteins leads to a highly localized β2-AR signaling 
pathway to modulate sarcolemmal L-type Ca2+ channels in rat ventricular myocytes30. 





Figure 2. Cartoon describing β1-ARs and 
β2ARs signaling pathways in 
cardiomyocytes. Gs coupled β1-ARs 
activates PKA through the production of 
cAMP resulting in positive chronotropic and 
inotropic effects. Secondly, activated CaMKII 
can induce apoptotis with increased 
catecholamine stimulation. In contrast, anti-
apoptotic signaling through Akt is mediated 
by Gi dependent β2-ARs. Both β-ARs are 
regulated by GRK2 leading to receptor down-
regulation in case of chronic activation. Taken 




apoptosis induced by sustained sympathetic Gs mediated stimulation
31. One theorized, that 
the switch of the β2-AR to Gi coupled survival pathway via phosphoinositide 3-kinase 
(PI3K)/Protein Kinase B (Akt) may be caused by PKA phosphorylation of the receptor and 
serve as a protective mechanism against catecholamine cardiotoxicity32. In heart failure, β1-
ARs start to get desensitized via ligand stimulated phosphorylation by associated G protein-
coupled receptor kinases (GRKs)33. GRKs prepare the activated receptor for internalization 
via the recruitment of β-arrestin (β-Arr)34, and the receptor loses its functional quality in 
addition to their desensitization by GRKs in spite of the increased circulation of 
catecholamines35-37. On the other hand, β2-ARs may support the failing/aging heart by 
enhancing myocardial contractility38,39 (Figure 2).   
The β3-AR is found primarily in adipose tissue where it is coupled to Gs-proteins
40, and little in 
the heart. Previous studies in β1/β2AR-KO mice have suggested, that the Isoprenaline (non-
selective β-AR agonist, Iso) induced β3-AR signaling leads to very modest cardiac 
contractility and seems to desensitize more rapidly than does signaling by either the β1AR or 
the β2AR
41
. Conversely, the cardiac-restricted overexpression of β3-AR in a transgenic mouse 
model showed enhanced cardiac contractility after treatment with a selective β3-AR agonist
42. 
Reasons for disparities in β3-AR effects may be attributed to the use of different compounds 
and different transgenic animal models. It has been reported that β3AR couples to Gs- and 
Gi-proteins in diverse cell types
43,44. Recently, it was also demonstrated that cardiomyocyte 
expression of this receptor is increased in rodent and human failing heart and it might be 
cardioprotective by its coupling to Gi and nitric oxide synthase-dependent NO/soluble 























1. 1. 2 cAMP - one second messenger with several functions 
 
Discovered in 1958 by Earl W. Sutherland and co-workers47 cAMP remains to be interesting 
for many researchers as a universal second messenger that produces different physiological 
effects depending on cell nature and composition. cAMP plays central roles in memory 
formation48 and mid brain system49, the secretion of insulin from pancreatic cells50,51, 
regulation of gene expression52 and metabolism53, immune reactions54 and most important 
for this work: cardiovascular regulation55. These effects can even be opposing in different cell 
types. For example, cAMP increases cardiac cell contractility but relaxes airway and vascular 
smooth muscle cells56. Moreover, studies on rat ventricular myocytes provided first insights 
into the idea of the spatially segregated cAMP signals organized in microdomains containing 
several proteins as molecular components of the signaling pathway (see section 1. 1. 3). 
Briefly, cardiomyocytes stimulated by the β-adrenergic agonist isoprenaline (Iso) or by 
prostaglandine E1 led to comparable amounts of synthesized cAMP resulting in PKA 
activation in both cases, but only Iso treated cells augmented cardiomyocyte contractility. 
The conclusion was that prostaglandine E1 mediated cAMP showed no classical substrate 
phosphorylation (especially at cardiac troponin I) due to the activation of different pools of 
PKA within the cardiomyocyte57. Likewise, cAMP signals elicited from glucagon receptors 
were demonstrated as not being involved in cardiac contractility in contrast to cAMP 
generated through β-ARs after Iso stimulation, which was another example of functionally 
distinct AC/cAMP/PKA microdomain58. The idea that not all cAMP pools and its respective 
downstream effects in the heart are equal, was established and demonstrated in several 
other studies on cardiac myocytes23,59,60. As mentioned above, there are differentially 
localized PKA subsets of PKA type I and PKA type II61, defined by their varying subunit 
isoforms and by differential binding to a variety of A-kinase anchoring proteins (AKAPs). This 
anchor proteins can also bind phosphodiesterases (PDEs), enzymes responsible for cAMP 
degradation, ensuring localized complexes and specific physiological responses to any given 
cAMP stimulus62. Next to the idea that cAMP has physical membrane barriers formed by 
different kind of organelles inside the cell63,64, PDEs have a key role in shaping intracellular 
gradients of cAMP and disabling random cAMP diffusion65.  
Most studies were focused on comparing cAMP dynamics between soluble and particulate 
fractions66,67, but it was also clear that the β-AR-AC-cAMP-PKA signaling pathway is not 
uniformly active at the plasma membrane either. For example, there are differences in lipid 
raft (cholesterin and sphingolipid rich planar domains) and non-lipid raft membrane 
domains10,68. Caveolae (omega shaped membrane invaginations) represent a special type of 
cardiac lipid rafts, containing caveolin (Cav) proteins as main components. These membrane 
domains have been shown to harbor β-AR-cAMP pathway components important for Ca2+ 





type Ca2+ channel (LTCC) in the heart71. Furthermore, studies demonstrated that such 
gradients of cAMP specifically derived from β2-ARs
29 activate a subset of protein kinase A 
molecules anchored in proximity to T-tubules72 (large sarcolemmal invaginations at Z-lines of 
cardiomyocytes). Cardiac LTCCs are proposed to be a sarcolemmal substrates of PKA73,74 
and presumably organized in cardiac T-tubules together with NKA and NCX75-78. There is an 
increasing body of evidence that PLM is a central player in the sympathetic response by 
kinase dependent inhibition of the NKA activity and indirect regulation of the cellular calcium 
load and inotropy of the heart15. In this context, elements important for the local tailoring of 
cAMP concentrations to distinct compartments and protection of possible substrates against 

























1. 1. 3 cAMP compartmentation in the heart - role of Phosphodiesterases and AKAPs 
 
The compartmention of cAMP derived signals in functional microdomains and their specific 
effects are widely recognized and demonstrated in different kinds of cells over the years. 
Most remarkable attempt showing local PDE activity in distinct intracellular microdomains 
was by whole cell patch clamp recordings which indicated a local PDE dependant cAMP pool 
Figure 3. Cartoon depicting the differential role of cardiac cAMP in confined microdomains leading to 
differential phosphorylation of PKA targets. During the action potential, Ca
2+





 release from the SR facilitating Ca
2+
 binding to troponin I (TnI) at myofilaments 
and contraction
151










 during diastole. Upon β-AR stimulation, cAMP activates PKA, which phosphorylates several 
downstream targets important for the cardiac excitation contraction coupling such as LTCC, RyR2, PLN, 













involved in β-AR stimulation of LTCC currents in frog ventricular myocytes70. Aberrant cAMP 
signals and changes in highly regulated microdomains may occur in diseased cells and 
contribute hypertrophy and heart failure79. For this reason it is of extreme importance to 
maintain the architecture of positively and negatively cAMP modulating and scaffolding 
proteins in the given microdomains.  
PDEs as cAMP degrading enzymes catalyze its hydrolysis and are critical for shaping the 
cAMP pools in mammalian cells65,80. This enzyme superfamily is comprised of 11 families 
and 70 different isoenzymes, which are encoded by 21 genes81. Cardiac myocytes express 
several PDE families: PDEs 1-5, 8 and 982,83. PDEs are categorized in their affinity and 
catalytic rates, in which PDEs 1-3 can hydrolyze both cAMP and 3´,5´-cyclic guanosine 
monophosphate (cGMP), while PDE4 and 8 are cAMP specific and PDE5 and 9 show a high 
selectivity for cGMP. Besides their kinetics, various PDE enzymes have differences in 




PDE inhibitors are commonly used to characterize subcellular contributions of PDEs to cAMP 
hydrolysis and spatio-temporal dynamics72,85, dissecting their key roles in shaping 
intracellular microdomains (see section 1.4).  
In particular, PDE1 has three subfamilies (PDE1A, PDE1B and PDE1C). PDE1 enzyme 
activity is increased via Ca2+/calmodulin binding at the regulatory domain in the N-terminus, 
PDE1 is also often referred to as the Ca2+/calmudilin stimulated PDE86. Having different 
affinities for both cyclic nucleotides (dual substrate specificity), PDE1 isoenzymes are 
believed to be important in the crosstalk between the second messenger Ca2+ and cyclic 
nucleotide signaling87. Albeit PDE1 has been suggested to play a role in cardiac disease88,89, 
Table 1. Cardiac PDE enzyme specifications and kinetic properties; Km = Michaelis-Menten constant,    












PDE2 cGMP stimulated, dual specifity 30-50 10-30 
PDE3 cGMP inhibited, dual specifity 0.02-0.15 0.18 
PDE4 cAMP-specific 2.9-10 - 
PDE5 cGMP-specific - 1.0-6.2 
PDE8 cAMP-specific 0.15 - 





there is still a need for potent selective PDE1 inhibitors to better investigate a possible 
cardioprotective effect.  
PDE2 is another dual specific enzyme family with three cardiac isoforms (PDE2A1-3). cGMP 
can enhance the catalytic activity of PDE2 through binding to a special regulatory domains at 
the N-terminus, referred to as GAF domains90 (found in: cGMP-specific phosphodiesterases, 
Adenylyl cyclases and FhlA). Via an allosteric binding mechanism, this leads to a direct 
increase of cAMP hydrolysis (positive cGMP/cAMP crosstalk). Mongillo and co-workers have 
found that PDE2 is strongly involved in cGMP/cAMP interplay after β-adrenergic 
stimulation91. Using real time Fluorescence Resonance Energy Transfer (FRET)-based 
imaging in neonatal rat cardiomyocytes, they showed that 'cGMP activated' PDE2 modulation 
of cAMP was potentiated upon cGMP production via the β3-AR/NOS/cGMP pathway which 
exhibited a negative inotropic effect after beta-AR stimulation in neonatal rat 
cardiomyocytes91. Furthermore, studies in ventricular myocytes of guinea pigs92 and 
ARVMs93 have supported their findings that PDE2 is highly membrane associated.  
In contrast to PDE2, cGMP inhibits the hydrolyzing activity of PDE3 for both cyclic 
nucleotides. This competitive inhibition provides a means by which an increase in cGMP may 
lead to an increase in cAMP and its differential effects in spatially distinct subcellular 
domains (negative cGMP/cAMP crosstalk)94. PDE3 comprises two subfamilies PDE3A and 
PDE3B. Although both are present in cardiomyocytes, PDE3A is the main subfamiliy95 
responsible for cardiac hypertrophy96 and contractility which is typically augmented by PDE3 
inhibition97. PDE3 are described to be in the cytosolic fractions as well as membrane bound 
isoenzymes, depending on the isoform PDE3A1 (membrane and soluble), A2 or A3 (both are 
only membrane bound)98,99. However, PDE3A is found mainly at the SR/endoplasmic 
reticulum rather than at the plasma membrane100. PDE3 is a dual specific enzyme and 
displays high affinity for both cAMP and cGMP, having higher catalytic activity for cAMP than 
for cGMP101. A decrease in PDE3 expression is thought to have adverse effects on the heart 
as it promotes cardiomyocyte apoptosis and impairs cardiac dysfunction induced by chronic 
pressure overload102. PDE3 and PDE4 contribute the majority of the cAMP catabolism in 
cardiomyocytes65.  
PDE4, the cAMP specific PDE, is the most diverse PDE family with four encoding genes 
(PDE4A, B, C and D) and around 20 splice variants103. In the mammalian heart, three out of 
four genes (PDE4A, B and D) encode for PDE4 isoenzymes102,104. The N-terminal regulatory 
domain determines the subcellular localization of the PDE4 isoforms105 and at the same time 
makes them essential players in cAMP compartmentation in cardiomyocytes. With the N-
terminal regulatory/localization domain PDE4 variants are able to form local cAMP signaling 
hubs by binding to scaffolding proteins such as β-Arr or AKAPs and through direct interaction 





tubules in the mouse heart, thereby controlling the β-AR stimulation of the L-type Ca²⁺  
current and the phosphorylation of the LTCC via PKA106. There is evidence that the PDE4D3 
isoform and the PKA reside in the same signaling complex through their association with the 
muscle-selective A-kinase anchoring protein (mAKAP), which in turn enhances the PDE 
activity, forming a unique negative feedback control over rising of local cAMP in 
cardiomyocytes107. Moreover, PDE4D3 was found in the cardiac RyR2/calcium-release-
channel complex108. Playing a key role in cellular desensitization mechanism for GPCRs (see 
section 1.1.1), PDE4D5 has been demonstrated to recruit β-Arr to the β2-AR upon receptor 
stimulation109,110. The PDE4D8 isoform was reported to form signaling complexes with β1-
ARs until binding of an agonist110. Phosphoinositide 3-kinase γ (PI3Kγ) is another newly 
identified regulator of PDE action. It controls local β2-AR-cAMP responses by activation of 
the cardiac PDE4A, PDE4B and PDE3A isoforms through PKA. By doing this PI3Kγ recruits 
the regulatory subunit of PKA to and the PDE isoforms, respectively, to the functional 
signaling complex. The absence of PI3Kγ showed hyperphosphorylation of the L-type 
calcium channel (Cav1.2) and phospholamban which resulted in proarrythmic changes
111.  
PDE5 is one of the most intensively studied enzymes for cGMP hydrolysis. PDE5 inhibitors 
show some benefits in hypertrophy and heart failure112,113. There are clinically used PDE5 
inhibitors officially approved for treatment of erectile dysfunction (PDE5A resides in the 
corpus cavernosum114) and pulmonary hypertension115. The three known isoforms PDE5A1-3 
also contain a regulatory GAF domain with binding sites for cGMP like PDE2 does, but this 
leads to a stronger increase in cGMP catalytic activity in contrast to PDE284. One other 
difference between both cGMP hydrolyzing PDEs is the subcellular distribution (cGMP 
compartmentation); Castro et al. demonstrated that PDE5 controls cGMP originating from the 
particulate pool of guanylyl cyclase (GC),  whereas PDE2 controls cGMP in the soluble 
fraction93. 
PDE8 is another cAMP-specific PDE in the mammalian myocardium, which is encoded by 
two genes (PDE8A and PDE8B). PDE8A is highly expressed in testis and ovary of mouse 
and human cells116,117, whereas PDE8B is found to be expressed specifically in thyroid 
glands118 in humans. PDE8 is distinguished from other cAMP specific proteins in the heart 
(PDE4) by its insensitivity to most of the PDE inhibitors including Isobutyl-1-methylxanthin 
(IBMX), however it can be inhibited by dipyridimole116. In the heart, PDE8A can be 
phosphorylated by the PKA holoenzyme119, similar to PDE4. Additionally, the same 
isoenzyme plays a regulatory role in the calcium transients during the ECC120.  
The fifth PDE family PDE9 contain a cardiac PDE9A which is a high affinity cGMP-specific 
phosphodiesterase expressed at the mRNA level in healthy human but not in mouse heart121. 
This new phosphodiesterase is similar to PDE8A regarding its insensitivity to most of the 





recent studies that unlike PDE5A, PDE9A can regulate cardiac cGMP signaling independent 
of the nitric oxide pathway and selective targeting of PDE9A could protect against sustained 
pressure-overload stress in cardiac diseases122.  
A-Kinase Anchoring Proteins (AKAPs) are highly important in cardiac cAMP signaling 
amplitude and duration. Several cardiac AKAPs have been described as functionally 
essential scaffolding proteins, which selectively localize cAMP mediated PKA signaling to 
subcellular microdomains123-126 (Figure 4). At least 15 AKAPs were identified in cardiac cells, 
most of which are involved in recruiting PKA isoforms, PDEs and protein phosphatases 
(PPs) in order to confine relevant signaling complexes in the heart127. AKAP18α is found in 
association with the LTCC to facilitate the PKA-dependent phosphorylation of the channel at 
the sarcolemma73. AKAP79/150 (in human/murine cardiomyocytes) assembles large 
signaling complexes with PKA, calcineurin, Cav-3 and AC at the T-tubular area, thereby 
facilitating PKA phosphorylation of LTCC, RyR2; and even PLB phosphorylation is AKAP150 
dependent at its Cav-3 associated domains128,129. Confinement of β-AR/cAMP signals, 
phosphorylation and dephosphorylation of PLB at the SERCA2 compartment is achieved 
through AKAP18δ130,131. Additionally, PKA anchoring via AKAP9 (Yotiao) to the K+ channel is 
highly important in terms of rapid cardiac repolarization of cardiomyocytes132. PKA 
phosphorylation of the potassium channel is regulated by PDE4D3, also recruited by Yatiao, 
navigating cAMP effects on the K+ channel activity133. As mentioned above, muscle-selective 
mAKAP mediate the dynamics of PKA activation within the RyR2 complex tightly regulated134 
by PDE4D3 and by AC5 activities135, since both enzymes can directly bind to this anchoring 
protein. In this context, it has been demonstrated that mAKAP mediates PKA-induced 















Figure 4. A-kinase anchoring 
proteins (AKAPs) controlling 
subcellular cAMP microdomains 
in the heart. Important AKAPs 
contributing to cAMP 
compartmentation and targeted PKA 
phosphorylation of key-regulatory 
proteins of the cardiac ECC. Taken 








1. 1. 4 Changes of local cAMP signaling and β-AR subtype modules in cardiac 
hypertrophy 
 
Rat model of congestive heart failure (CHF) syndrome after myocardial infarction (MI) is the 
most commonly used experimental model to study the alteration and progression of cardiac 
physiology during progression to heart failure136. By ligation of the left anterior descending 
artery, a method usually used for creating cardiac ischemia137, irreversible myocardial injury 
and loss of cardiac myocyte function is observed in the infarct area. With ventricular 
remodeling and resulting hypertrophied cardiac muscle, the heart compensates for the 
diminished oxygen supply without losing much of its contractility138 (compensated 
hypertrophy). This compensatory response is limited by the degree of infarct size; for 
example, if very large amounts of myocardium become necrotic, there is not enough 
hypertrophy to normalize myocardial volume. To sustain normal perfusion pressure, the 
renin-angiotensin-aldosterone system is activated promoting ventricular remodeling, 
progressive dilatation and deterioration in myocardial function139,140 (decompensated 
hypertrophy). The sympathetic activation of β-AR receptors is a critical component of the 
progression of heart failure, being a 'good' response under stress (“fight-or-flight” response) 
or for acute myocardial infarction to maintain cardiac performance, but is recognized as 
detrimental in a long-term view141,142. As mentioned before, in response to accelerated 
release of catecholamines in progressive heart failure, there is desensitization and reduction 
of β-AR density in the myocardium37,143. 
Studies have shown that remodeling during the development of heart failure after MI starts at 
the cell membrane level, where the T-tubular network is altered144,145 leading to impairment of 
cAMP microdomains and subtype-specific β-AR signaling during heart failure. By combining 
scanning ion conductance microscopy (SICM) with the FRET based imaging technique, 
Nikolaev et al. have demonstrated a redistribution of β2-AR and normally highly confined β2-
AR mediated cAMP signals from T-tubules to detubulated membrane areas 29,146. Impaired 
β2-AR regulation via PI3Kγ controlled PDE3-dependent cAMP pools close to the plasma 
membrane was demonstrated to be a potential cause of ventricular arrhythmias which are 
often observed in heart failure111. 
During cardiac disease alterations in cAMP compartmentation and scaffolding by AKAPs and 
PDEs are observed. Several groups have shown that the PKA association with AKAPs is 
decreased in heart failure, for example due the pathological decrease in PKA-R subunit 
autophosphorylation147, which in turn decreases cardiac troponin I phosphorylation in the 
failing human and animal heart148,149. Disruption of the macromolecular complex of 
mAKAP/RyR/FKBP2.6/PDE4D3 leads to increased sensitivity to Ca2+ in failing human hearts. 
It has been demonstrated, that this can be either caused by distinct dissociation of 





maladaptive changes of the cAMP sensitive PDE4D3 localization due to pathophysiological 
changes of the heart108; both resulting in a 'leaky' RyR and consequent arrhythmogenesis by 
disturbed Ca2+ handling152. Interestingly, it has been suggested that mAKAP/RyR2 
participates in early cardiac myocyte hypertrophy by adrenergic receptor signaling153. 
Evidence provided by several groups have proven that different stages of impaired cardiac 
performance, from early disease stage (compensated hypertrophy) to the stage of chronic 
heart failure, are reflected by changes of PDE microdomain action in terms of expression and 
localization. Using a transgenic mouse model of caveolin targeted FRET biosensor Perera et 
al. uncovered cGMP-sensitive PDE2 and PDE3 redistribution between β1-AR- and β2-AR-
associated membrane microdomains with unaltered whole-cell PDE expression and activities 
in early cardiac disease (Figure 5B). Recent experiments by Sprenger et al., demonstrated 
local increase in cAMP dynamics at the PLB/SERCA2a due to PDE3 and especially PDE4 
down-regulation in order to compensate for the loss of SERCA2a function in the early 
disease mouse model. Furthermore it was indicated that the decreased PDE4 effects are 
replaced by local PDE2 responses during sympathetic stimulation, which suggest protection 
of the heart and especially the SERCA2a compartment against elevated cAMP levels in 
hypertrophy154. 
Consistent with this notion, Mehel et al. showed that there is a significant PDE2 expression in 
human failing hearts, which constrains the effects of long-term β-AR stimulation on 
cardiomyocyte Ca2+ handling and contractility in HF155.  
By contrast, the expression and activity of other cAMP-hydrolyzing enzymes, PDE3 and 
PDE4, are significantly down-regulated102,156. Under HF conditions, both the lower PDE3 
levels promoting enhanced cardiomyocyte apoptosis and higher compensating PDE2 activity 
in late stage HF (Figure 5C) could be a consequence of increased cGMP, which is produced 
by guanylyl cyclase (GC) stimulated with increased levels of natriuretic peptides in 
hypertrophy. 
PDE3A is suggested to be down-regulated in HF157 which results in induction of a 
proapoptotic transcriptional repressor gene156 in the PDE3 regulated cAMP-dependent 
nuclear microdomain. Treatment with PDE3 inhibitors (especially in congestive heart 
failure158) improves cardiac contractility but increases mortality rate due to arrhythmias and 
sudden cardiac death159.  
Despite these detailed insights about alterations in global and local PDE effects (Figure 5) 
160, there is little known about changes of individual subtype-specific β-AR dependent PDE 
regulation of cAMP signaling to the vicinity of the cardiac PLM-NKA complex. This topic 




























1. 2 Differential regulation of the Na/K-ATPase by Phospholemman in the microdomain 
 
1. 2. 1 The cardiac sodium pump  
 
Discovered in 1957 by J.C. Skou the sarcolemmal 
sodium-potassium ATPase (NKA)161 is the predominant 
efflux source for cardiac sodium which maintains the 
transarcolemmal sodium gradient and provides a  rapid 
upstroke of action potential162. This gradient ensures 
proper ion homeostasis, critical for sodium dependent 
membrane transporters  (for example, Na+/glucose 
cotransporter) and for normal cellular function163. The 
action of the sodium pump regulates physiological 
electrical activity influencing the sodium-calcium 
exchanger (NCX) and cardiac contractility164 (Figure 6). 
The NKA extrudes three sodium ions from the cytosol to 
the extracellular domain in exchange for two potassium 
ions particularly to restore the steady-state intracellular 
sodium concentration at 4-8 mM (10-15 mM in rat and 
mouse)165 at the expense of metabolic energy driven from the hydrolysis of ATP166. This ion 
exchange results in one net charge generating a membrane current. For the quantification of 
sodium pump mediated (i.e., ouabain-suppressible) transport the K+ analogue 86Rb 
(Rubidium) is often used as a tracer for K+ and gives reliable results167.  
A B C 
Figure 5. Alterations of local cAMP signaling in compensated hypertrophy and heart failure. (A) In healthy 
cardiomyocytes, cAMP is acting at major Ca
2+
 handling proteins, forming microdomains which contain local pools 
of PKA anchored to AKAPs and specific PDE isoenzymes. β2-AR signals are predominantly located around LTCC 
in the T-tubules, whereas β1-AR signals originate from the surface membrane producing far-reaching cAMP 
acting in subcellular microdomains (e.g. to SERCA2a) by means of scaffolding proteins. (B) In compensated 
hypertrophy (early stage of HF), the total PDE activities are unaltered, albeit local decreases at cAMP 
compartments (PDE3 at β2-AR and PDE3/PDE4 at SERCA) and specific relocations occur (e.g. PDE2 between 
β1- and β2-AR). (C) In heart failure (chronic cardiac disease), structural deformation of T-tubules and alterations in 
global and local PDE/PKA effects next to down-regulation and/or desensitization of β1-AR take place. There is a 
decrease in receptor-microdomain coupling and functional cAMP responses. Taken from Froese et al.
145
. 
Figure 6. NKA - an integral player in 
the 'fight-or-flight' response. 
Enhancement of Na/K-ATPase activity 
limits the rise in intracellular Na
+
 caused 
by the higher level of Na
+
 influx during 
action potential. By doing so, NKA limits 
the rise in cellular and SR Ca
2+
 load by 
favoring Ca
2+
 extrusion via the Na/Ca 
exchanger. Inhibiting the NKA via 







Upon action potential Na+ and Ca2+ enter the cell through voltage gated ion channels, which 
triggers Ca2+ from the sarcoplasmic reticulum (SR). Elevated Ca2+ triggers cellular contraction 
in the systole, which is followed by diastolic Ca2+ extrusion mainly via the NCX in forward 
mode which in turn is promoted by the NKA pumping Na+ out of the cell to keep the Na+ 
levels constant164. Hence, cellular Ca2+ levels, that are highly important for the regulation of 
the ECC, are linked to the NKA activity. Elevated intracellular sodium would favor reverse 
mode of NCX resulting in larger calcium transient and contractility162. Since the 18th century 
this mechanism is made use for cardiotonic steroids. For example, digoxin as NKA inhibitor, 
induces acute cardiac inotropy and is used for treatment of heart failure168. Several groups 
have shown that a small transmembrane protein called phospholemman (PLM) interacts with 
the NKA and modulates it activity, analogous to phospholamban (PLB) at SERCA169, another 
P-type pump170-174. Upon β- adrenergic stimulation in the heart, PLM works against 
cardiomyocyte sodium and calcium overload primarily by disinhibiting the NKA (discussed 
below).  
 
1. 2. 2 Cardiac subunit expression and composition of the Na pump 
 
Solving of the crystal structure of the NKA in 
2007175-177 revealed new insights about structure 
and composition of the cardiac sodium pump. In 
mammalians, four α (α1, α2, α3, α4) and three β 
(β1, β2, β3) isoforms are recognized as minimum 
operative subunits (SUs)178,179. Having binding 
sites for Na+, K+, ATP and cardiac glycosides the 
catalytic α-SU assembles with the β-SU, which is 
highly important for structural and functional 
maturation of the sodium pump180, and one of the 
seven isoforms of the so called 'Fixid' proteins 
(FXYD), titled according to their conserved 
phenylalanine-X-tyrosine-aspartate motif181,182. 
This functional multi-subunit enzyme (Figure 7) 
differs in tissue specific composition, proving that 
the sodium pump plays a key role in multiple 
regulatory mechanisms involving critical Na+ 
transport under different physiological conditions. 
Predominant isoforms in the heart are α1, α2 and 
β1 having FYXD1 (PLM) as regulatory protein 
Figure 7. Structure of the Na/K-ATPase. The 
NKA consists of an intracellular α- SU (encircled 
in light brown) and extracellular β-SU (encircled 
in blue). The applied color on the quaternary 
changes gradually from the N-terminal (blue) to 
the C-terminal (red). Having a great 
transmembrane domain, the regulatory subunit of 
the pump (FXYD1-PLM) is red and associated 
with the α SU. The transmembrane domain 
contains binding sites for 3 Na
+
 and 2 K
+
 ions, 
respectively, which pass sequentially through the 









(see section 1. 3. 1)180,181,183. It is proposed that the different α isoforms vary in subcellular 
distribution and function. Berry et al. have previously shown that, the NKA with the α1 SU 
(NKA-α1) is more to be found on surface membrane compartments and provides around 88% 
of the total Na+ current. Even though the NKA-α2 has a high functional T-tubular density being 
five times more present in the cardiac T-tubules than in the sarcolemma, the NKA-α1 still 
generates at least 50% of cardiac T-tubular Na current in mice184. Referring to their 
differential distribution in addition to their clear physical and functional association with the 
NCX185-187, the α1 and α2-SUs are suggested to have different functional roles in cardiac 
myocytes: The NKA-α1 is responsible for global Na
+ current, as it is the predominant isoform 
of the two, simultaneously it controls subsarcolemmal Na+ microdomains together with the 
NKA-α2  especially at the dyadic cleft located at the sarcoplasmatic reticulum
166,188. Also, it is 
stated that the α2  isoform preferentially regulates cardiac Ca
2+ transients via the NCX189-191. 
There is the intriguing idea of microdomains created by co-localization of ion transporters, 
where the NKA is regulated by PLM75,192,193. It is supported by the fact that there is an indirect 
influence of the NKA isoforms on sub-sarcolemmal Na+ controlled by the NCX which has 
already been suggested to be functionally linked to the NKA192. Additionally, it is stated that 
the cytoskeletal protein ankyrin B anchors NCX to the membrane actively forming a 
functional complex with the NKA and the IP3-receptor supports75,193. 
 
1. 3 Kinase mediated control of Phospholemman over the Na+/K+-ATPase  
 
1. 3. 1 Phospholemman- FXYD1 Protein 
 
As stated above, the NKA is regulated by different cellular mechanisms, for example by 
sodium and potassium levels or membrane potential as well as factors like ATP availability 
and cardiac steroid binding. Next to this, it is regulated by FXYD1, a small membrane protein 
belonging to a family of proteins with 7 identified members (FXYD1-7) being firstly defined as 
regulators for ion transporters and named according to the aforementioned signature FXYD 
motif in the N-terminus182 (Figure 8). At least five of these proteins are described as auxiliary 
subunits regulating NKA activity in a tissue- and isoform-specific way194. FXYD1, also known 
as phospholemman (PLM), is a 72 amino acids long single transmembrane protein, 
predominantly found in heart, skeletal and smooth muscle cells195-198. The N-Terminus with 
its 17 amino acid residues lies in the extracellular domain, whereas the C-Terminus resides 
in the cytosolic fraction with 35 amino acids. Bearing multiple phosphorylation sides at the 
COOH terminus PLM is phosphorylated at the Ser68 residue by PKA and PKC199,200. The 
latter has additional phosphorylation targets at the Ser63 and Ser/Thr69 residues174. Physical 
association of PLM was demonstrated by co-immunoprecipitation with the α-SU of the NKA76 





which is also a PKA substrate whereupon the SERCA2a is disinhibited, but PLB does not 
alter the maximum transport rate (Vmax) of its pump like PLM does for NKA. Several 
laboratories have shown that PLM phosphorylation relieves the sodium pump by possibly 
increasing Vmax
174,202-204 and Km for Na
+ ions (increased Na+ affinity)15,76,200,205,206. Variation 
between studies regarding Vmax/Km showed discrepancies most likely due to different 
methodology performed in different labs.  
Several other functional roles are ascribed to PLM in the heart166. It is suggested that PLM 
modulates the gating of L-type Ca channels (Cav1.2) in an overexpression model207. Another 
study on cardiac cells revealed that PLM oligomerizes208, as originally proposed but instead 
of forming ion channels in Xenopus oocytes209 and regulating cell volume in cultures cardiac 
cells by forming taurine efflux channels210, it is rather accepted to oligomerize199 in order to 
generate a 'storage pool' to increase 'responsiveness' of a certain PLM-free NKA population 
in the heart to adrenergic stimulation, by as yet unidentified means166. 
Under catecholamine stress PLM works against of arrhythmogenesis although minimally 
causing negative inotropy by promoting Na extrusion211,212. For this reason PLM expression 




Figure 8. Amino acid sequence of currently known mammalian FXYD proteins. 
Human FXYD sequence alignments showing seven known families with conserved residues (in red).  
The PKA/PKC phosphorylation domain of phospholemman is framed. Taken from Cornelius et al.
182 
 
1. 3. 2 Kinase phosphorylation of Phospholemman  
 
In 1985 PLM was identified as a PKA and PKC phosphorylatable protein in the heart213,214. 
Initially, it was assumed that the NKA is regulated through phosphorylation of its α-SU via 
PKA, but it was strictly dependent on a detergent which makes the  PKA phosphorylation site 
of the pump accessible215. It is now generally accepted that phosphorylated PLM activates 
the cardiac sodium pump and tonically inhibits it at its basal state76. Conclusive analysis of 






showing pump activity 
mechanisms under β-AR 
stimulated and non-stimulated 
conditions216. The β-AR 
stimulation of PLM-WT cells 
increased Na+ pump activity 
and Na+ affinity to levels of 
NKA current of PLM-KO cells, 
where there was no inhibitory 
effect of PLM to the NKA 
enzyme. Additional 
experiments introducing a 
phosphorylated PLM peptide to 
cardiomyocytes of the same animals have indicated that Ser68 phosphorylation of PLM can 
even stimulate Na+ pump current above basal levels, simultaneously indicating that the final 
19 amino acids of PLM are sufficient to inhibit the NKA202. Phosphorylation of PLM leads to a 
change in orientation, but the FXYD1 protein remains physically associated to the α1-SU of 
the cardiac sodium pump, which is co-immunoprecipitated in several studies76,171,217,218. It is 
widely known that similarly to PLM dependent PKA activation of the Na+ pump, protein 
kinase C (PKC) mediated phosphorylation of PLM increases Vmax with a change in Na
+ 
affinity of the NKA in some cases172,200. There are speculations that PKC acts on a different 
pool of PLM predominantly associated to the α2 isoform of the pump. The pump isoform 
specific effect of PLM phosphorylation via PKC is a theory demonstrated in several 
experiments from different labs172,205 which still remains questionable. It is supported by the 
fact that for instance PKC phosphorylation increases the maximum rate of the α2-NKA but not 
α1-NKA in genetically modified SWAP mice (where α1-NKA can be blocked by ouabain), and 
contradicted by FRET experiments showing no actual change between YFP-PLM and CFP-
α1 and -α2, respectively
205. PLM phosphorylation at its multiple target residues by PKA and 
PKC turns out to be additive200, also in terms of NKA function. Investigations in ARVMs have 
shown high basal phosphorylation of PLM (~30% at Ser68 and ~50% at Ser63) mainly 
caused by the PKC activity, hence basal Ca2+ levels174. Three PKC isoforms are identified in 
the heart (PKCα, δ, and ɛ)174. Fuller et al. demonstrated that receptor-mediated PKC 
activation causes sustained phosphorylation of Ser63 and Ser68, but transient 
phosphorylation of Thr69, which leads to further stimulation of the sodium pump174. There is 
evidence that exogenous/endogenous NO mediates PKCɛ dependent PLM phosphorylation 
thereby limiting Na+ and Ca2+ overload and related cardiac diseases219. 
Figure 9. Phosphorylation of phospholemman regulates sodium 
pump activity. Signaling pathways mediating kinase and 
phosphatase activities involved in the PLM phosphorylation state. PKA 
and PKC phosphorylate PLM, hence stimulate the sodium pump, 
whereas PP-1 and PP2-A activity inhibit the pump by 
dephosphorylating PLM. ET-1, endothelin 1; ETA, endothelin A 







The kinase phosphorylation of phospholemman, in particular during sympathetic stimulation 
is essential for the ECC17 where the phosphoprotein disinhibits NKA15,203 (Figure 9) while 
actively inhibiting the NCX173,220 thereby regulating intracellular Ca2+ concentration critical for 
cardiac function221. 
 
1. 4 Changes of PLM/ NKA complex in diseased heart 
 
The importance of NKA function in the heart in terms of trans-membrane sodium gradient is 
demonstrated by several laboratories (see section 1. 2. 2). It is well known that Na+ overload 
contributes to cardiac diseases such as ischemia/reperfusion222,223 hypertrophy and heart 
failure (HF)224-226. Elevation in intracellular Na+ which occurs largely through several sodium 
influx pathways shown to be up-regulated in the failing myocardium227,228, may contribute to 
the negative force-frequency relationship, slowed relaxation and arrhythmias190. A large body 
of data suggests that this may be caused by a reduction of NKA activity and compromised 
Na+ extrusion via the pump in heart failure229,230. Additionally, aberrant phosphorylation of 
PLM231, the expression of NKA and its α subunits contribute to the disease pattern217. There 
are different studies by groups focused on different stages of the disease process in human, 
canine and rat heart failure models226,232,233. For example, Bossuyt et al. showed that the 
PLM fraction phosphorylated at Ser-68 was dramatically increased in a rabbit HF model217. 
Comparable results were obtained in studies on murine cells 3 weeks post-MI by Mirza et al. 
This group observed a decrease in PLM expression, accompanied by an increase in the 
fraction of phosphorylated PLM in murine hearts 3 weeks post-MI234. Additionally, the 
enhanced NCX activity in PLM-KO-MI cells largely accounted for the improvement in cardiac 
and myocyte contractility compared to WT-MI hearts234. El-Armouche et al. reported 
significantly reduced PLM phosphorylation, which could possibly be involved in disease 
progression linked to an increase in Inhibitor-1 and Protein Phosphatase-1 (PP-1) activity, 
but there was no change in expression for total PLM or the α1-SU in failing human hearts
231. 
Similarly, data presented by Boguslavskyi et al. clearly indicate that the complete prevention 
of PLM phosphorylation sites via a PLM mutant knock-in mouse subjected to aortic 
constriction markedly exacerbates cardiac remodeling by further inhibiting the NKA230. 
Pointing out the aforementioned preferential role of the α2-NKA in EC coupling (section 1. 1. 
2), the same group230 and others235 have revealed that the increase in α2-SU expression is a 
positive adaptive mechanism possibly allowing the normalization of ion, especially Ca2+, 
regulation in response to Na+ overload caused by hypophosphorylation of PLM in animals 







1. 5 Imaging local cyclic nucleotide dynamics 
 
1. 5. 1 Fundamentals of Förster/Fluorescence resonance energy transfer 
As mentioned in section 1. 1. 3, it is widely accepted that spatial and temporal 
compartmentation of cAMP is important for targeting a range of proteins in functionally 
important subcellular locations. Measuring second messenger levels via biochemical assays 
such as radioimmunoassays directly detecting cAMP content in a cell pellet236-238 or indirect 
immunoblot analysis of phosphorylated proteins by the respective kinases (i.e. PKA) are 
alternative ways used to measure cAMP concentrations239. Offering poor spatial resolution, 
these classical methods do not enable to obtain results of physiological relevant free cAMP 
effects but rather total amounts of cAMP in lysed tissue, not focusing on single cells let alone 
cellular compartments. As most cellular activities appear in milliseconds, there was an urge 
to gain insights into cAMP dynamics at high temporal resolution. 
Most commonly used live cell imaging techniques are based on the Förster resonance 
energy transfer (FRET) phenomenon, discovered by the German physicist Theodor Förster 
in 1948240. The Förster equation                        describes the non-radiative 
energy transfer between two fluorophores in very close proximity (< 10 nm) which has 
provided a popular mean to detect protein-protein interaction and conformational change of 
proteins in living cells. More precisely, the donor fluorophore is excited with a specific 
wavelength of light matching its peak of absorption. The excited donor in turn transfers its 
emission energy to the acceptor fluorophore (Figure 10A). Therefore, a FRET pair should 
necessarily consist of two fluorophores, by which the donor fluorophore emission spectrum 
should overlap with the excitation spectrum of the acceptor fluorophore241. The well-known 
Jablonski diagram (Figure 10B) demonstrates in detail the excited S1 state of the donor 
electron and the its fall back to ground state S0 via emission of fluorescence energy in form 
of a photon exciting the acceptor fluorophore on a energetically lower level242. Similar to its 
donor pair, the excited acceptor electron emits fluorescent light when returning to its singlet 
ground state S1. According to the change in energy state, the donor fluorescence (emission) 
intensity is reduced and the acceptors emission is increased. For quantification of FRET 
occurring between the pair of fluorophores, the ratio acceptor emission intensity/donor 
emission intensity or vice versa is calculated, and a change in FRET can be observed during 
experiments239. FRET pairs often consist of green fluorescent protein (GFP) mutants, such 
as cyan fluorescent protein (CFP) as the donor protein and yellow fluorescent protein (YFP) 
as the acceptor protein. Tagged to sequences of proteins of interest, these fluorophores 
allow through optical recordings to monitor dynamic protein-protein interactions243 (Figure 
10C)171,201. FRET between CFP and YFP sandwiching cyclic nucleotide binding domains was 

















1. 5. 2 cAMP sensitive FRET Biosensors 
 
Before starting to generate (targeted) cAMP sensitive FRET based biosensors, several 
groups have used the change in cAMP dependent LTCC70 and CNGC102,244,245 currents as a 
readout for local cAMP dynamics and significantly contributed to characterization of β2-AR-
cAMP pools shaped by PDEs (i.e. PDE3 and PDE4)246. Adams et al. created the first 
chemically labeled cAMP sensitive sensor called FliCRhR, utilizing the regulatory and 
catalytic subunits of the PKA holoenzyme. Injecting it to living cells, cAMP activity is 
monitored through PKA dissociation and loss of FRET247. The more practical genetically 
encoded PKA based biosensor was developed by Zaccolo et al., who fused CFP and YFP to 
the R and C subunits to detect cAMP changes close to the Z-lines in neonatal rat ventricular 
myocytes72,248. It was the first attempt to monitor distinct PDE activities in subcellular 
microdomains. This sensor showed slow kinetics and probable interaction with endogenous 
PKA (Figure 11). Subsequently, several single cAMP binding site based sensors were 
A B 
C 
Figure 10. The principles of FRET instancing the CFP and YFP pair. (A) The prerequisite for FRET to occur 
is a spectral overlap between the donor and acceptor fluorophore. The emission spectrum (blue) of the donor 
fluorophore (CFP) overlaps with the excitation spectrum (yellow) of the acceptor fluorophore (YFP) and allows 
fluorescence resonance energy transfer (FRET). The overlapping spectral area is colored grey. Taken from 
Piston et al.
225
 (B) The schematic representation of the Jablonski-diagram describes the transfer of fluorescence 
energy from the donor to the acceptor fluorophore. Upon absorption of photon energy, the donor electron moves 
from a ground state (S0) to its excited state (S1). The donor fluorophore can partly transfer its energy from the 
lowest S1 state in form of fluorescent energy. The electrons of the acceptor fluorophore with a lower energetic 
excitation spectrum and close proximity is excited. Acceptor electrons are lifted from their S0 to the S1 state and 
yellow fluorescence light is emitted when the acceptor electrons “fall back” into their S0 state.
226 
(C) FRET is 
utilized for tracking dynamic protein-protein interactions and conformational changes within a single protein. 







developed, which can monitor cAMP in the bulk cytosol. For example, the HCN2-camps 
sensor28 contained the soluble C-terminal cAMP binding domain from the cyclic nucleotide-
gated potassium channel 2 flanked with CFP and YFP sites enabling real time 
measurements of cAMP dynamics in the bulk cytosol. Additionally, either Epac1 or Epac2 
ased single chained biosensor with uniform cellular expression were widely used to detect 
rapid cAMP signals developing in the cytosol249,250. Fused to CFP and YFP, a single cAMP 
binding domain changes its conformation upon cAMP leading to a decrease of the FRET 
signal. Epac1 and Epac2 based sensors differ in their cAMP affinity and FRET capacity. 
Despite its lower cAMP affinity, Epac1 based sensor E1-camps showed a larger FRET 

























Figure 11. Cartoon showing means to determine 
intracellular cAMP dynamics. (A) Regulatory and 
catalytic subunits of PKA probes dissociate upon 
cAMP binding causing a decrease in the FRET signal. 
The Epac based FRET sensor has CFP and YFP in 
close proximity at basal state, after cAMP binds to the 
unimolecular sensor, there is a conformational shift and 
FRET-based YFP emission decreases. cAMP signals 
can be measured through determination of cyclic 
nucleotide gated channel currents by patch-clamp 
methods, or by imaging with a Ca
2+
-sensitive dyes. (B) 
Compared with PKA-based probes, the Epac-based 
sensors exhibit an extended dynamic range and have 
better signal-to-noise ratio. FRET changes detected with 
the CNGC method are more transient and have a 
greater temporal resolution although they are restricted 






1. 6 Aims of the project 
Previous studies have demonstrated that several cAMP-dependent PKA substrates 
important for the regulation cardiac ECC are organized in microdomains formed by 
scaffolding proteins and -adrenergic receptor subtypes. However, the knowledge about the 
real time dynamics of cAMP in a microdomain coupled to PLM and NKA, its interaction with 
β-ARs and individual cardiac PDE families forming this important microdomain as well as 
their alterations in cardiac disease is insufficient.  
 
Therefore, the aims of this work were: 
 
1. To develop a FRET-based Phospholemman targeted cAMP biosensor PLM-E1 and to 
express it in ARVMs using an adenoviral expression system. 
 
2. To perform real time monitoring of cAMP dynamics in the PLM/NKA compartment in 
order to understand the regulatory mechanisms behind a possible local restriction of β-AR 
mediated cAMP signals in the PLM/NKA microdomain.  
 
3. To study microdomain-specific alterations of cAMP signaling at the PLM/NKA complex 
























2. Materials and Methods 
 
2. 1 Materials  
 
2. 1. 1 Cells 
HEK293A       Invitrogen 
HEK293      Sigma Aldrich 
 
2. 1. 2 Plasmids 
 
pcDNA3.0      Invitrogen 
Epac1-camps      Prof. Viacheslav Nikolaev 
humanPLM      Prof. Michael Shattock 
caninePLM-YFP      Dr. William Fuller 
humanPLM-E1 long linker    this project  
caninePLM-E1 short linker    this project 
Gateway® pDONR™ 221     Invitrogen  
Gateway® pAd/CMV/V5-DEST™    Invitrogen 
 
2. 1. 3 Bacteria strains 
 
One Shot® TOP10 chemically competent E. coli  Invitrogen  
One Shot® OmniMax2T1     Invitrogen 
 
2. 1. 4 Animals 
 
Adult male 8-12 weeks old Wistar rats (250 - 300 g; Charles River) were held on site (Animal 
Care Facility, UMG Göttingen). They were maintained in compliance with the constitutional 
animal protection act (Tierschutzgesetz, TSchG). All animals were kept in containment 
rooms at room temperature. Between 4 and 6 rats were housed in each cage, allowing free 
access to food and water. All animal protocols were approved by the local University Medical 
Center Göttingen animal protection committee and all animal work was performed according 
to institutional and governmental guidelines. 
Adult male 8 weeks old Sprague Dawley rats (~ 200 g) were used for introduction of the 
heart failure rat model and underwent heart isolation 16 weeks post MI, as described in 
sections 2. 2. 18 and 2. 2. 19. Aged matched control animals (AMC) were ordered both at 







2. 1. 5 Oligonucleotides 
 
The human PLM sequence was kindly provided by Prof. Michael Shattock, King´s College 
London. 





















Which includes the canine PLM, the linker and the YFP sequences 
 


























2. 1. 6 Chemicals 
 
Acrylamide (Rotiphoreses Gel 30)   (ROTH) 
ANP      (Bachem) 
Ampicillin      Roth, # K029.1  
Ampuwa® water     Fresenius Kabi Deutschland GmbH  
BAY 60-7550      Santa Cruz, # sc-205219 
β-Mercaptoethanol     Sigma, # M3148 
Bromphenol Blue sodium salt   Applichem, # A1120  
8-Br-2’-O-Me-cAMP-AM    Biolog, # B028  
2,3- Butanedione monoxime   Sigma, # B0753 
Bumetanide     Sigma, #B3023-250MG 
Calcium chloride    Sigma, # C4901-1KG-D 
Calcium chloride dihydrat    Merck, # 17257 
CGP-20712A methanesulfonate salt  Sigma, # C231  
Cilostamide      Sigma, # C7971 
Dimethyl sulfoxide DMSO    Sigma, # D2650 
dNTPs      Promega, # U1240  
EDTA       Roth, # 8040.3 
Ethanol Rotipuran >99,8%    Roth, # 9065.1 
EZ-Link™ Sulfo-NHS-SS-Biotin  Thermo Fischer, # 21331 
Forskolin      Sigma, # F6886 
GFP-Trap® A     Chromotech, # gta-10  
Glucose      Sigma, # G7021  
Glycerol      Sigma, # G8773  
Glycine      Roth, # 3908.3  
H-89 dihydrochloride hydrate   Sigma, # B1427 
HEPES      Sigma, # H4034  
Hydrochloride acid 37%    Sigma, # 84422  
ICI-118.551 hydrochloride    Sigma, # I127 
3-Isobutyl-1-methylxanthin    Applichem, # A0695  
Isoproterenol hydrochloride    Sigma, # I6504  





LB- Agar powder Miller    Applichem, # A0927  
LB- Medium powder Miller   Applichem, # A0954  
Loading buffer DNA IV (for Agarose gels)  Applichem, # A3481  
Kanamycin     Applichem, # A1493 
Magnesium chloride    Sigma, # M8266-1KG 
Magnesium chloride hexahydrate   Applichem, # A1036 
Magnesium sulfate heptahydrate   Sigma, # M2773  
MDL-12,330A hydrochloride    Sigma, # M182  
Methanol      Roth, # HN41.2  
8-methoxymethyl-3-isobutyl-1- 
methylxanthine     Sigma, # M2547  
Milkpowder      Roth, # T145.1  
Monensin sodium salt   Sigma, # M5273-1G 
N-Methyl-D-glucamine   Sigma, # 66930-100G 
N,N,N′,N′-Tetramethylethylenediamine 
(TEMED)     Sigma, # T9281  
Octaethylene glycol monododecyl ether Sigma 
Ouabain octahydrate    Sima, # O3125-1G 
peqGOLD Universal Agarose   Peqlab, # 35-1020  
PhosStop      Roche, # 04906837001  
Ponceau S      Sigma, # P3504  
Potassium bicarbonate    Sigma, # P7682  
Potassium chloride     Sigma, # P5405  
Potassium dihydrogen phosphate   Merck, # 4873 
Protease Inhibitor Cocktail    Roche, # 11872580001  
Protein G Sepharose 4 Fast Flow  GE Healthcare, #17-0618-01 
Protein Marker V     Peqlab, #27-2211  
Quick-Load® 100bp DNA ladder   Biolabs, # NO467S  
Quick load® 1 kb DNA ladder   Biolabs, # NO468S  
Rolipram      Sigma, # R6520 
Rubidium-86 Radionuclide   Perkin Elmer, # NEZ072001MC 
Sodium azide      Sigma, # S2002  
Sodium bicarbonate     Sigma, # S5761  
Sodium chloride     Sigma, # S5886 
Sodium hydroxide     Roth, # 6771.3 
Streptavidin Sepharose High Performance GE Healthcare, # 17-5113-01 





Taurine      Sigma, # T8691 
TRIS       Roth, # 4855.3  
Triton-X® 100     Applichem, # A1287.0025  
Tween-20®      Sigma, # P1379  
Vectashield® Mounting Medium   Vector Laboratories, # H-1000 
 
2. 1. 7 Cell culture 
 
Geneticin® Selective Antibiotic  
(G418 Sulfate) (50 mg/mL)   Thermo Fischer #10131027 
DMEM, 4.5 % glucose    Biochrom, # F0445  
FCS       Biochrom, # S0615  
Glutamine      Biochrom, # K0283  
Iscove Basal Medium    Biochrom, # FG 0465  
Lipofectamine®2000 Reagent  Invitrogen, # 11668  
Modified Medium 199    Sigma, #M7528 
OPTI-MEM®     Gibco, # 11058  
PBS Phosphate Buffered Saline  
(Dulbecco)      Biochrom, # L1825  
Penicillin/Streptomycin    Biochrom, # A2213  
Plaque GP Agarose     Biozym, # 850110  
Trypsin/ EDTA solution    Biochrom, # L2143 
 
2. 1. 8 Enzymes and Kits 
 
Pfu DNA Polymerase (2-3 U/μL)   Promega, # M774B 
Restriction enzymes for molecular  
cloning     New England Biolabs 
Pierce BCA Protein Assay Kit   Thermo Scientific, # 23227  
Plasmid Midi Kit     Qiagen, # 12945  
Plasmid Mini Kit     Qiagen, # 12125  
Proteinase K      Applichem, # A3830-0500  
QIAquick Gel Extraction Kit    Qiagen, # 28704  
QIAquick PCR purification Kit   Qiagen, # 28104 









2. 1. 9 Antibodies 
 
Table 2. Primary antibodies are used for Western Blot (WB) and immunofluorescence (IF) analysis. Antibodies 
for Western Blot analysis were diluted in the used blocking buffer (TBS + 1% Tween + 5% milk powder) and for 
immunofluorescence  experiments in appropriate blocking buffer (PBS +10% FCS + 0.2% Triton-X-100). 
Antibody Dilution Company 
anti-α1 mouse monoclonal C464.6 Western Blot: 1:10000 
Immunofluorescence: 1:100 
Millipore, # 05-369 
anti-FXYD1 (PLM) rabbit polyclonal Western Blot: 1:10000 
Immunofluorescence: 1:100 
Abcam, # ab76597 
anti-GFP rabbit monoclonal  Western Blot: 1:10000 Abcam, # ab32146 
anti-PDE3A goat polyclonal Immunofluorescence: 1:100 Santa Cruz, # sc11834 
 
Table 3. Secondary antibodies were diluted in buffers prepared for the used primary antibodies for WB and IH 
analysis. 
Antibody Dilution Company 
Alexa Fluor® 488 donkey anti-goat  Immunofluorescence: 1:500 Invitrogen, # A11055 
Alexa Fluor® 633 goat anti-rabbit Immunofluorescence: 1:500 Invitrogen, # A21070 
Alexa Fluor® 488 goat anti-rabbit Immunofluorescence: 1:500 Invitrogen, # A11034 
Alexa Fluor® 633 rabbit anti-mouse Immunofluorescence: 1:500 Invitrogen, # A21063 
Immun-Star™ goat anti-mouse- 
HRP  
Western Blot: 1:5000 Biorad, # 170-5047 
Immun-Star™ goat anti-rabbit- 
HRP  
Western Blot: 1:5000 Biorad, # 170-5046 
 
2. 1. 10 Microscope devices and software 
 
Attofluor® cell chamber    Invitrogen  
AxioObserver A1 epifluorescence microscope  Carl Zeiss MicroImaging  
Axiovert 200 microscope     Carl Zeiss MicroImaging  
CFP/YFP filter set      Chroma Technology  
CoolLED 440 nm      CoolLED  
CoolSNAP-HQ CCD-camera    Visitron Systems  
DualView filter slider      Photometrics  
ImageJ Software      National Institutes of Health  
Inverted fluorescent microscope    Nikon  
710 NLO microscope     Carl Zeiss MicroImaging  





Corporation Oil immersion 63x objective   Carl Zeiss MicroImaging  
ORCA-03G camera      Hamamatsu Photonics  
ZEN 2010 Software      Carl Zeiss MicroImaging 
 
2. 1. 11 General devices and software  
 
AlphaImager® software     ProteinSimple  
Biotek Reader (for BCA assay)    BIOTEK Instruments  
Centrifuges       Thermo Scientific  
MS-Excel      Microsoft  
MS-PowerPoint      Microsoft  
MS-Word       Microsoft 
MultiImage Light Cabinet     Alpha Innotech Corporation  
NanoDrop 2000      Thermo Scientific  
Powerpac HC      Biorad  
Thermocycler       Sensoquest  
ThermoMix compact      Eppendorf  
Ultracentrifuge L-70      Beckman 
iCycler       Biorad  
Mini-PROTEAN® Electrophoresis System   Biorad  
Mupid-One Gel Electrophoresis    Unit ADVANCE Co., Ltd.  
Origin Pro 8.5 Software     OriginLab Corporation  
pH meter       Inolab  
TRI-CARB 4910TR     Perkin Elmer Inc., # A491000 
Ultracentrifuge L-70      Beckman  
UV Table IL-350-M      Bachofer  
Ventilator Minivent      Hugo Sachs Electronic  
X-Ray Film processor     SRX 101A Konica 
 
2. 1. 12 Other materials 
 
Dialysis Tubing for virus dialysis    Medical International Ltd.  
Eppendorf tubes      Eppendorf  
Cryogenic Vials, Nunc    Thermo Scientific, #5000-0012 
Falcon tubes       BD Falcon  
Fiber pads for Western blot     Bio Rad, #1703933  
Filter Unit 0.2 RC Spartan 13 0.2 μm  





Forene®       Abbott  
21-gauge needle      BD Microlane  
26-gauge needle      BD Microlane  
Gauze       Th Geyer, # 9.068291  
Glass Cover Slips 24 mm     Thermo Scientific, # 004710781  
Heparin 25000 I.E./5 ml    Rotexmedica    
Microscope Slides      Thermo Scientific, # J1800AMNZ  
Medical X-Ray      Film Fujifilm, # 4014403 7 
Pony Vial      Percin Elmer, Inc., # 6000292 
Prolene suture 6-0      Ethicon  
Protran Nitrocellulose Transfer Membrane   Whatman, # 4018650  
Quickseal Centrifuge Tubes (virus centrifugation)  Beckmann, # 342413  
Scintilation Liquid Lumasafe Plus    Lumac LSC, # 3097  
Serological pipettes      Sarstedt  
Slide-A-Lyzer Dialysis Cassettes, 10K MWCO  Thermo Scientific, # 66383 0.5ml  
Spacer Plates for Western blot    Bio Rad, #1653311  
Steriflips       Millipore, # SCGP00525  
Short Plates for Western blot    Bio Rad, #1653308  
Temgesic®       Essex Pharma GmbH 
U-40 Insulin 30Gx1/2     Braun, # 40012525  
U-40 Insulin Omnifix Solo     Braun, # 9161309v  
Water bath       Julabo  
6 Well Plates       Starlab, # CC7682-7506  
12 Well Plates     Greiner Bio One, # 665180 
96 Well Plates      Nunc, # 167008  
96 Well Plate for MicroBeta     Perkin Elmer, Inc. #1450-401 
 
2. 1. 13 Buffers and solutions 
 
All buffers were prepared with deionized H2O, if not indicated otherwise 
 
Name       Ingredients 
Plasmid dialysis  
EB Buffer in Ampuwa water     Tris-HCl   10 mM 
       pH 8.5 
TE Buffer in Ampuwa water     Tris-Cl   10 mM 
       EDTA    1 mM 





Transformation of component cells 
5x KCM buffer     CaCl2    150 mM 
       MgCl2    250 mM   
       KCl    500 mM 
LB Medium      LB medium powder  25 g/L 
       Ampicillin   100 µg/mL 
LB plates      LB agar powder  40 g/L 
       Ampicillin  100 µg/mL 
 
Transfection of HEK293A cells 
 
2x BBS      Na2HPO4  1.5 mM 
sterile filtrated      BES   50 mM 
       NaCl   280 mM 
       pH   6.95 (NaOH) 





10x Sucrose buffer     Tris   24.22 g 
       MgCl2x6H2O  8.13 g 
       D(+) Sucrose  800 g 
       pH   8 




FRET buffer      NaCl   144 mM 
       KCl   5.4 mM 
       MgCl2   1 mM 
       CaCl2   1 mM 
       HEPES  10 mM 







2. 2 Methods 
 
2. 2. 1 Generation of the recombinant plasmids and adenoviral construction of           
E1-camps and PLM-E1 biosensors 
 
The development the cytosolic cAMP sensitive adenoviral biosensor was based on the 
already published DNA construct encoding for Epac1-camps249. This gene construct consists 
of a special nucleotide binding sequence (E157-E316) from the human Epac1 protein. We 
targeted the E1-camps biosensor to the PLM/NKA microdomain by using a special cloning 
strategy and thoroughly optimized the new PLM targeted FRET biosensor, which promised 
direct monitoring of cAMP dynamics in the vicinity of PLM. Following cloning strategies are 
used to produce reliable PLM-targeted biosensors and adenoviral constructs to monitor 
FRET changes in the vicinity of PLM (see sections 2. 2. 7-2. 2. 9).  
 
2. 2. 2 PCR- Polymerase chain reaction 
 
To amplify DNA sequence of interest and introduce restriction sites to DNA sequences 
during cloning, following PCR reaction was applied. 
H2O      81 μl     
10x Pfu buffer    10 μl  
dNTPs 10 mM    2 μl  
for. Primer (25 μmol/L)   2.5 μl  
rev. Primer (25 μmol/L)   2.5 μl  
DNA  sequence (200 ng)   1 μl  
Pfu DNA Polymerase   1 μl 
Following PCR protocol was applied: 
(94°C for 5 min, 30 x (94°C for 30 s, 55°C for 30 s, 72°C for t), 72°C – 7 min) possible over 
night storage at 4 °C. 
The elongation time (t) was dependent on the length of the desired PCR product and used 
enzyme (Pfu polymerase replicates 1 kb in 2 min).  
 
2. 2. 3 Gel electrophoresis, DNA purification and quantification 
 
A very important mean to analyze DNA sequences or to generate DNA segments for ligation 
and cloning, digestion with Type II restriction enzymes (New England Biolabs) was 
performed according to manufacturer´s instructions. The available New England Biolabs 
buffer (NEBuffer) chart from the manufacturer simplified choosing the correct buffer for a 






control digestion of DNA for 0.5 h at 37°C: 
500 ng template (or 8 μL from a mini-preparation) 
1.5 μL NEBuffer (suitable for both enzymes) 
0.25 μL restriction enzyme 1 
0.25 μL restriction enzyme 2 
ad 15 µL H2O 
The DNA segments were run on a 1% agarose gel and analyzed quantitatively using the 
Multi Image Light Cabinet Transilluminator (Alpha Innotech Corporation). 
 
segmental digestion of DNA for cloning: 
6–8 μg of vector plasmid or template DNA 
5 μL NEBuffer 
2.5 μL of restriction enzyme 1 
2.5 μL of restriction enzyme 2 
ad 50 μL H2O 
digestions were incubated over night at 37°C 
 
DNA was isolated by gel electrophoresis (2. 2. 4), extracted and eluted in 50 μL EB-buffer 
(vector fragment) or 25 μL EB-buffer (insert). 
 
2. 2. 4 Gel electrophoresis, DNA purification and quantification 
 
Upon generating the PCR product or digestion with restriction enzymes, the DNA fragments 
were run on a 1% agarose gel (TAE buffer including 0.5 μg/ ml ethidium bromide) at 100-150 
V. 1000 bp ladder (Quickload) was run in parallel, as DNA marker. Documentation of the 
results were prepared as a picture and printed out from the system. The DNA molecules 
were separated according to their size, DNA segment of interest were excised with a scalpel 
and extracted and purified using the QlAquick Gel Extraction Kit according to the 
manufacturer’s protocol. The DNA was eluted in TE-buffer (or EB-buffer after BP and LR 
reaction). The Nanodrop device was utilized to determine the DNA concentration. 
 
2. 2. 5 Ligation 
 
Inserting DNA fragments into a vector plasmid with matching restriction ends requires the 










T4 DNA Ligase     1 μL 
vector (1 μg)      1 μL 
digested insert(s)/or digested PCR product(s) 11.5 μL 
10x ligase reaction buffer    1.5 μL 
overnight incubation at 14°C 
 
For a triple ligation, the different molecular masses of the used inserts are crucial to calculate 
vector-to-insert ratios. In this case, two insert samples are used in 11.5 µl in a ratio adjusted 
to their molecular weights to provide equimolar amounts. 
 
2. 2. 6 Transformation of competent bacteria cells 
 
The generated plasmid DNA sequence was introduced into One Shot® TOP10 chemically 
competent E. coli or One Shot® OmniMax2T1 (for BP and LR reaction) incubating following 
reaction mix for 50-60 min at 37°C. 
 
E.coli competent cells 100 µL  
Ligation Mix    15 µL 
H2O    65 µL 
5x KCM Buffer   20 µL (see 2.1.13)  
 
The reaction mix was incubated on ice for 20 min followed by 10 min at RT. To simplify 
bacterial growth, 1 mL of LB medium (without antibiotics) was added to the mixture and 
incubated at 37°C in a ThermoMixer (700 rpm), pelletized and resuspended in 100 µL of the 
aspirated supernatant (LB medium without antibiotics). Thereafter, the suspension was 
spread on ampicillin selective LB- medium plates (kanamycin selective plates are used after 
BP reaction) and colonies were grown overnight at 37°C and harvested in order to be raised 
in 4 mL LB medium with ampicillin (kanamycin) overnight at 37°C. The next day plasmid 
DNA was precipitated out of the bacteria using the Qiagen Plasmid Mini Kit for a 2 mL 
volume of bacterial suspension. Subsequent DNA restriction analysis demonstrated positive 
clones, which were used grown in 30 mL of LB medium with ampicillin over night at 37°C and 
plasmid DNA was extracted using the Qiagen Plasmid Midi Kit. The concentration of DNA 







2. 2. 7 Cloning the humanPLM-E1 FRET biosensor based on the pcDNA3 Epac1-camps 
construct 
 
Our aim was to target the cytosolic cAMP sensor to the PLM microdomain via fusing it to the 
C-terminus of a full length human PLM sequence via a flexible linker GSGSAS. For this, the 
Epac1-camps plasmid was double digested with HindIII and EcoRI restriction enzymes to 
remove the N-terminal YFP sequence. The following two inserts were amplified by PCR:    
1.) Full human PLM sequence without stop codon was amplified using the primers 
PLMHindIIIfor and PLMNheIrev; 2.) YFP sequence was amplified using YFPNheIfor and 
YFPEcoRIrev primers. The PCR products were run on an 1% agarose gel, purified and 
digested with HindIII/NheI and NheI/EcoRI, respectively, as described in 2 .2. 4. After DNA 
purification, both extracted and predigested DNAs of PLM and YFP were triple ligated with 
the HindIII/EcoRI digested pcDNA3-Epac1-camps vector sequence.  
 
2. 2. 8 Cloning the caninePLM-E1 FRET biosensor based on the PLM-YFP construct 
 
After some initial experiments detailed in section 3. 1, an optimized sequence of the PLM-E1 
biosensor was designed with the help of Dr. William Fuller, who kindly provided an 
alternative PLM-YFP sequence having a longer flexible linker between PLM and YFP. To 
retain this liner sequence KRSRAQASNSAVDGTPVATG, 6 μg of the given PLM-YFP vector 
was double digested with KpnI and NotI. Two inserts were prepared by: 1.) PCR 
amplification of the YFP sequence using the pEYFP-N1 vector as a template with the primers 
PLMYFPKpnIfor and YFPEcoRIrev as described in 2. 2. 2. The PCR product was purified 
and digested with KpnI and EcoRI; 2.) 10 µg of the Epac1-camps plasmid were digested with 
EcoRI and NotI to obtain the second fragment which includes Epac1-CFP sequence. Both 
digested fragments and the vector were run on a 1 % gel and the DNA was extracted using 
the Qiaquick Gel Extraction Kit. To ligate the pEYFP N1 caninePLM-linker vector, eluted in 50 
μl elution buffer, with the YFP and Epac1-CFP fragments, each eluted in 25 μl elution buffer, 
following mix is prepared for an overnight ligation at 14°C:  
 
pEYFP N1 caninePLM-linker (~4200 bp)  1 μl  
YFP (~700 bp)    6.5 μl  
Epac1-CFP (~1200 bp)    5 μl  
T4 Ligase buffer 10x     1.5 μl  






2. 2. 9 Generation of the adenoviral constructs Epac1-camps, humanPLM-E1 and 
caninePLM-E1 
 
The adenovirus generation is performed via the Gateway® Cloning system and in 
accordance with the manufacturer´s instructions. 
The sequence of interest embedded in the pcDNA3.0 or pEYFP-N1 vector was amplified by 
PCR using specially designed primers with flanking attB sequences.  
 
Epac1-camps and humanPLM-E1   caninePLM-E1  
H2O      81 μl   H2O      81 μl 
10x Pfu buffer    10 μl   10x Pfu buffer    10 μl 
dNTPs 10 mM    2 μl   dNTPs 10 mM    2 μl 
pcDNA3attBFor (10 pmol/μl)  2.5 μl   attBPLMhundfor (10 pmol/μl) 2.5 μl  
pcDNA3attBRev (10 pmol/μl)  2.5 μl   attBYFPN1rev (10 pmol/μl)  2.5 μl  
pcDNA3 biosensor DNA (200 ng)  1 μl   pEYFP N1 PLM-E1 (200 ng)  1 μl  
Pfu DNA Polymerase   1 μl   Pfu DNA Polymerase   1 μl  
 
The PCR reaction was as follows:  
94°C 5 min  
94°C 30 sec  
55°C 30 sec        x 30  
72°C 4 min 30 sec (4 min for Epac1-camps) 
72°C 7 min 
 
PCR product were separated on a 1% agarose gel and purified; the DNA concentration was 
determined with the Nanodrop system. Each of the constructs were introduced into the donor 
vector Gateway® pDONR™ 221 (attP) with in vitro recombination reaction (BP reaction) by 
means of the Gateway® BP Clonase™ II Enzyme Mix.  
The cloned vector was transformed into One Shot®OmniMax2T1 bacteria and grown 
overnight at 37 °C on a kanamycin selective LB-medium plate. The grown colonies were 
selected and amplified, as described in 2. 2. 6. The control digestion was performed with 
EcoRI/EcoRV for Epac1-camps and humanPLM-E1 as well as with KpnI/NotI for caninePLM-E1. 
To generate the virus expression vector containing the biosensor DNA construct, the BP 
reaction product was further recombined with pAd/CMV/V5-DEST™ through the LR-reaction 
overnight at 25°C. The LR product with the final recombinant adenoviral vector DNA was 
grown in One Shot®OmniMax2T1 cells and selected by using ampicillin instead of 
kanamycin LB-medium plates. The positive clone was identified by restriction enzymes 





Following mixtures are prepared and incubated overnight at 25°C. 
 
BP reaction      LR reaction 
PCR eluate    80 ng   DNA    150 ng 
pDONR™ 221 vector   1 µL  pAd/CMV/V5-DEST™  1µL 
(150ng)      (150ng)  
TE-buffer     ad 8 µL TE-buffer   ad 8 µL 
BP Clonase II Enzyme mix  2 µL  LR Clonase II Enzyme mix 2 µL 
 
Before HEK293A transfection, Epac1-PLN adenoviral vector DNA was linearized as follows:  
 
DNA    5 μg  
10x buffer NEB1  2.5 μl  
100x BSA   0.25 μl  
PacI    2 μl  
H2O ad   25 μl  
 
Extraction of the DNA is achieved through ethanol precipitation of the digested vector. To 
initiate the precipitation by electrophilic interaction between negatively charged phosphate 
groups of the DNA and positively charged sodium ions in solution, 10 μl of 3 M sodium 
acetate solution was added to the digestion mix and incubated for 30 min at -20°C. At the 
same time, 70 μl of ice-cold 100 % ethanol was used as a less polar solvent than water to aid 
the functional groups to form stable ionic bonds and precipitate. After centrifugation for 10 
min at 13.300 rpm, the generated DNA pellet was washed with 500 μl ice-cold 75% ethanol 
and centrifuged again for 5 min at 13.000 rpm. In order to solubilize the DNA pellet, 10 μl 
H2O was added. The solution was used for transfection of a 10 cm plate with HEK-293A cells 
at 80% confluency by the Lipofectamine®2000 reagent (7 µL) in OPTI-MEM® (300 µL), 
incubated for 20 min at RT. After 7-14 days, virus production led to detachment of 
transfected HEK293A cells. The detached cells with virus were harvested by centrifuging for 
5 min at 800 rpm. The supernatant was used for further HEK293A transduction and virus 
amplification in Iscove Basal Medium (5% FCS, 1% antibiotic, antimycotic). Performing a 
ultracentrifugation of the lysed virus containing supernatant of HEK293A cells (40.000 rpm 
overnight at 16 °C, Beckmann Rotor Ti90). The virus was concentrated in a cesium chloride 
gradient during centrifugation. The developed virus band was collected using a 21 gauge 
needle and dialyzed in 10 x sucrose buffer. To determine physical virus concentration, the 
optical density (OD260) was measured. After diluting the virus solution 1:100 with sucrose 





a Plaque Assay (Cooper, 1961) the biological virus activity (plaque forming units per ml 
[pfu/mL]) was assessed. For this purpose, 6-well plates of HEK293A cells covered with 1.5% 
plaque GP agarose were prepared and transduced with virus at 10, 100 and 1000 pfu/well 
(calculated via physical virus concentration) and analyzed. Adult rat ventricular 
cardiomyocytes were isolated as described in 2. 2. 19 and transduced with the E1-
camps/E1-PLM virus (MOI 300). Imaging experiments were performed 48 h after 
transduction. 
 
2. 2. 10 Calculating the multiplicity of infection and adenoviral transduction of ARVM 
 
ARVMs were isolated as described (see section 2. 2. 19), counted in a Naubauer Chamber 
(Celeromics), seeded on 6-well plates and maintained in culture for 1-2 h. Approximately 1-
1.5 million ARVMs in total were used for transduction. In order to calculate the volume of 
virus to achieve the desired multiplicity of infection (MOI) for a specific amount of cells, we 
used the following equation: 
 
Adenovirus volume added (μl) = (Required MOI x number of cells)/(PFU/μl) 
 
The calculated amount was added to a volume of fresh culture medium necessary to cover 
the cells to be transduced (2 mL/well). The culture medium (Medium 199 supplemented with 
5 mmol/L taurine, 5 mmol/L carnitine, 5 mmol/L creatine, penicillin/streptomycin and L-
glutamine supplement) of ARVMs was replaced with the viral culture medium, and the 
ARVMs were further incubated with the adenovirus for 48h at 37°C and 5% CO2. In case of 
relatively high amount of dead ARVMs, the culture medium was replaced after 24 h.  
 
2. 2. 11 Cell culture and transfection of the HEK293A cell line 
 
In order to test newly developed FRET biosensors, HEK293A cells were cultured at 37°C 
and 5% CO2 using Dulbecco´s Modified Eagle’s Medium (DMEM medium) supplemented 
with 4.5 g/L glucose, 10% FCS, 2 mM L-glutamine, 100 U/mL penicillin and 100 μg/ml 
streptomycin. For passaging, cells were washed with sterile phosphate buffered saline 
(PBS), detached from the surface of the wells/flask using 2 mL 0.05% Trypsin (Invitrogen), 
resuspended and split in a ratio of 1:10 in fresh cell medium. 
Plated on coverslips in six well plates the HEK293A cells were ready for transfection in 24 h, 
when they reached 60-70 % confluency. In general, two different transfection methods were 
used, depending on the purpose of transfection: 1.) The CaCl2 method for having a 





method to accomplish enhanced transfection efficiency for protein overexpression and 
quantification analysis. 
 
2. 2. 11. 1 Transfection with CaCl2 under sterile conditions: 
 
10 μl of Plasmid DNA (1 μg/μl) were added to 440 μl of sterile H2O. The DNA dilution was 
mixed with 50 μl of 2.5 M CaCl2 and 500 μl 2x BBS. After 10 min incubation at RT, 166 μl of 
the mixture were added dropwise to each well. 
 
2. 2. 11. 2 Transfection with Lipofectamine 2000® under sterile conditions: 
 
Following the manufacturer's instructions for optimal transfection, 36 μl of the Lipofectamine 
2000® reagent were diluted with 846 μl Opti-Mem® Medium, and 1.2 μl of the DNA Plasmid 
(1 μg/μl) in 150 μl of the same medium. After mixing both dilutions, a DNA-lipid complex was 
allowed to develop for 20 min. Thereafter, 250 μl of the reaction mix was dropwise pipetted 
onto each well with HEK293 cells in culture medium and the experiments were conducted 
after a 24 h incubation at 37°C and 5 % CO2. 
To transfect cells with newly generated viral vectors (see section 2. 2. 9), the transfection mix 
contained 300 μL Opti-MEM, 5 μg linearized DNA in the pAd_CMV_V5DEST vector and 7 μL 
Lipofectamine 2000® reagent for a 10 cm plate of HEK293A cells. 
 
2. 2. 12 SDS-PAGE and Western Blot analysis  
 
Using SDS-PAGE, proteins were separated according to their size by sodium dodecyl sulfate 
polyacrylamide gel electrophoresis, whereas in Western Blotting, separated proteins were 
transferred from the gel onto a polyvinylidene fluoride or nitrocellulose membrane and 
analyzed for protein expression by using specific antibodies.  
 
Experimental methods for the project phase in London:  
 
For expression analysis of the humanPLM-E1 sensor to be examined, transduced HEK293 cells 
were lysed in 500 µL 2 x SDS sample buffer (100 mMol Tris, 4% SDS, 20% glycerol, 0.2% 
bromphenol blue, 5% β-mercaptoethanol in H2O, pH 6.8) per well (if not indicated otherwise), 
scraped and harvested into 1.5 mL tubes. Gels were prepared beforehand according to 
following instructions, starting with a 10% acrylamide (Protogel, National Diagnostics) 









   Table 4. Ingredients of the used gels for Western Blot analysis at King´s College London 
Ingredient Resolving gel (10 %) Stacking gel (4.5 %) 
Tris HCl (1M) pH 8.8 3.75 mL - 
Tris HCl (1M) pH 6.8 - 0.625 mL 
Acrylamide (30%) 3.33 mL 0.75 mL 
SDS (10%) 0.1 mL 50 µL 
TEMED 5 µL 10 µL 
APS (10%) 50 µL 80 µL 
H2O 2.76 mL 3.465 mL 
 
Protein samples and protein ladder (Precision Plus Protein TM Dual-Colour Standards [Bio-
Rad]) were run at constant 100 V for about 1.5 hours in SDS running buffer (0.025 M TRIS, 
0.19 M glycine, 1% SDS). The protein migration continued until the blue dye front reached 
the bottom of the resolving gel. The SDS-PAGE was performed using the Mini protean III 
Tetra Cell system (Bio-Rad). Upon separating the proteins according to size in the resolving 
gel, they were transformed onto polyvinylidene fluoride (PVDF) membranes (GE Healthcare) 
prerinsed with methanol and transfer buffer (0.025 M TRIS, 0.19 M glycine, 20 % methanol, 
0.1 % SDS). The gels on membranes were sandwiched between six layers of filter paper 
presoaked in transfer buffer. Next, the transfer in a Hoeffer TE77 semi-dry transfer unit was 
carried out at 10 V for 35 min with a current restricted to 250 mA per gel. 
The proteins were blocked against non-specific binding with PBST (PBS + 0.1 % Tween) + 
5% milk powder (Marvel) over night at 4°C, the membrane was then treated with relevant 
primary antibodies (diluted in blocking buffer) for 2 h at room temperature (RT). The specific 
dilutions for primary antibodies are detailed in Table 1. The membranes were washed for one 
hour (each washing step: 10-15 min). To visualize the resulting primary antibody binding, the 
probes were incubated with horseradish peroxidise (HRP)-conjugated secondary antibody 
(diluted in blocking buffer) for 2 h at RT. The specific dilutions for secondary antibodies 
incubations are detailed in Table 2. After another washing procedure for one hour, the 
membranes were ready for enhanced chemiluminescence (ECL) analysis. Here, the HRP 
conjugated antibodies formed a complex with the ECL reagent mixture, detected via 
Hyperfilm ECL high performance X-ray film (GE Healthcare) for different acquisition times 
and developed using a Fuji RGII automatic processor (Fuji). Upon scanning the protein 








Experimental methods for the project phase in Göttingen:  
 
Having produced the caninePLM-E1 FRET biosensor construct, SDS-PAGE/Western Blot 
analysis for characterization of expression and localization of the optimized sensor was 
performed. Apart from the following small modification, it was accomplished as at King´s 
College London. 
Cells (HEK293A or ARVMs) to be analyzed were lysed by 500 µL/well 3x SDS-sample buffer 
(200 mM Tris, 6 % SDS, 15 % glycerol, 0.3 % bromphenol blue, 10 % 2-mercaptoethanol in 
H2O, pH 6.7) and harvested. Next, 2 gels for SDS-PAGE analysis were prepared as follows. 
 
 
Table 5. Ingredients of the used gels for Western Blot analysis in UMG, Göttingen 
Ingredient Resolving gel (10 %) Resolving gel (12 %) Stacking gel (4.5 %) 
4x Tris/SDS pH 8.8 (500 
mmol/L Tris, 0.4 % SDS) 
3.0 mL 3.0 mL - 
4x Tris/SDS pH 6.8 (500 
mmol/L Tris, 0.4 % SDS) 
- - 940 µL 
Acrylamide (30%) 4 mL 4.8 mL 18.8 µL 
TEMED 18 µL 18 µL 7.5 µL 
APS (10%) 48 µL 48 µL 80 µL 
H2O 5 mL 4.2 mL 2.31 mL 
 
After running the proteins on a gel, they were transferred onto nitrocellulose membranes 
(Protran, Whatman) inside the Mini Trans-Blot Transfer Cell (Bio-Rad), filled up with ice cold 
transfer buffer (32 mM Tris, 192 mM glycine, 4 % methanol) and blotted for 2 h at 100 V. To 
precisely cut the membrane in order to detect multiple proteins for one probe, it was stained 
with Ponceau S solution (0.5% in 10% acetic acid) for 5 min, washed with water until bands 
appeared. As described above, the membrane had to be blocked against unspecific binding 
with 5% milk in TBST (TBS + 1 % Tween), this time at RT for 1h. The incubation with primary 
antibodies (for dilutions see section 2. 1. 9) was done at 4°C overnight. After membrane 
incubation with a HRP-coupled secondary antibody (see section 2.1.9) for an hour at RT and 
treatment with ECL (Thermo Scientific). Films (Fuji Medical X-Ray Films, Fujifilm) were 
developed using a film processor (SRX 101A Konica, USA) with varying exposure  times (1 








2. 2. 13 Co-immunoprecipitation 
 
With this co-immunoprecipitation (co-IP) protocol we were able to prove physical association 
of proteins expressed either in HEK293A cells or ARVMs. All samples are handled at 4°C 
during the entire procedure. The lysed protein amount used for one co-IP experiment was 
equal to cells from 1-3 wells of one six well plate (1 well for transfected HEK293A cells  and 3 
wells for  transduced ARVMs). 20-30 µL of the GFP-Trap® reagent (Chromotek) was washed 
5 x 1mL in lysis buffer containing 2 mg/mL octaethylene glycol monododecyl ester (C12E10) 
in co-IP buffer (1mM EDTA in PBS plus protease and phosphates inhibitors) and equilibrated 
overnight at 4°C. Upon lysing the cells in 500 µL co-IP lysis buffer, the cells were carefully 
scraped from the bottom of the well, agitated at 4°C and centrifuged (17000 g) for 5 min at 
4°C. The supernatant of the lysed centrifuged cells was incubated with the GFP-Trap® 
beads over night at 4°C. Thereafter, the beads were washed 5 times (1mL each) with 4°C 
co-IP buffer (0.5 mg/mL C12E10). The beads were then resuspended in 100 µL 2x SDS 
PAGE sample buffer supplemented with 5% β-mercaptoethanol.  
The same protocol was applied for co-IP analysis by means of primary antibody immobilized 
on Protein G Sepharose 4 Fast Flow® (GE Healthcare). 20 µL sepharose beads were 
washed with co-IP lysis buffer (5 x 1mL) and equilibrated overnight at 4°C (or for 1-2 h at 
RT). 1 µg of primary antibody was pre-immobilized on the beads, again over night at 4°C. 
The beads were incubated with solubilized and centrifuged supernatants of cells (HEK293A 
or ARVM) from 1-3 wells of a six-well plate overnight at 4°C. 
Collecting samples at each step throughout the entire procedure, including the multiple 
washing steps, was important to trail protein loss and to facilitate the comparative analysis of 














Figure 12. The co-Immunoprecipitation 
method.  Schematic demonstration of the 






2. 2. 14 Cell surface biotinylation 
 
Testing the cell surface expression of the PLM-E1 DNA construct was essential to prove 
correct localization and expression of the developed tagged FRET biosensor. A significant 
amount of biosensor protein was expected to reach the cell surface. To verify this, HEK293 
cells were seeded and cultivated as mentioned in section and transfected with the PLM-E1 
plasmid at a confluency of 65 %. One well of a six well plate was washed three times very 
slowly and carefully with 37°C PBS. Biotinylation solution (1mg/mL sulfo-SS-NHS-biotin in 
PBS) was added to the cells and incubated for 10 min at 37°C in incubator. After rinsing the 
cells to remove the excess biotinylation reagent, cells were lysed in 0.5 mL per well of 1% 
triton X-100 in PBS supplemented with protease inhibitors (lysis buffer) and lysed for 30 min 
at 4°C. Samples were transferred to tubes (scraped and harvested from plate surface) and 
spun down at 17500 G for 5 min at 4°C. The supernatant was kept for further analysis, 
additionally one sample (50 µL) was retained from it and mixed 1:1 with 2x SDS PAGE 
sample buffer without β-mercaptoethanol (refer to as starting material). The retained 
supernatant was added to Streptavidin-Sepharose beads. Beforehand ~30 µL beads per 
sample were washed multiple times, preequilibrated in lysis buffer at 4°C and recovered by 
centrifuging 1 min at 17500G 4°C. The beads were incubated with the supernatant of the 
lysed cell pellet for 1-4 hours at 4°C or overnight. The beads were spun down at 17500 G for 
2 min at 4°C. A small sample (100 µL) was taken and mixed 1:1 with 2x SDS-PAGE sample 
buffer with 5% β- mercaptoethanol (refer to as unbound fraction). The beads were washed 
with lysis buffer. Following final washing step, 100 µL 2x SDS-PAGE sample buffer with 5% 
β-mercaptoethanol was added. Before SDS-PAGE/Western Blot analysis, samples were 
heated at 60°C for 15 min to elute proteins in the bound fraction (refer to as beads fraction). 
 
2. 2. 15 Generation of a HEK293A cell line stably expressing PLM-E1  
 
Using the principle of selection via antibiotic resistance, HEK293A cells exclusively 
expressing the PLM-E1 construct were selected, propagated and stocked at -80˚C. 
HEK293A cells were seeded on a 10 cm dish to achieve around 75 % confluency overnight. 
On the next day, they were transfected with a mix of 300 µg DMEM Medium without 
supplements, 3 µg PLM-E1 DNA plasmid and 7 µL Lipofectamine 2000®. One day after 
transfection, the medium was changed to DMEM medium containing 4 µL/mL Geniticin 
antibiotic (50mg/mL, Thermo Fischer). Non-transfected cells usually started to detach during 
after one week of incubation at 37°C, while transfected cells started to form small colonies, 
which were detectable macroscopically and could be picked. Using a flexible tube and a 
pasteur pipette, the colonies were picked by sucking and blowing each of the colonies back 





overnight incubation at 37°C, cells were treated again with Genticin, which permitted PLM-E1 
expressing HEK293A cells to proliferate and to reach maximum confluency. Next, cells were 
transferred to a 6-well plate, and subsequently to a 10 cm dish to propagate the line. After 
sufficient amount of cells has been cultured, they were washed with PBS, trypsinized and 
resuspended in the 10 cm dish with 6 mL of DMEM culture medium without supplements, 1.7 
mL FCS and 0.7 mL DMSO. The cell suspension was devided into Kryocups (1mL), labelled 
and frozen at -80°C. 
 
2. 2. 16 Ouabain sensitive 86Rb uptake measurements 
 
We measured the ouabain sensitive 86Rb uptake as a surrogate for potassium to determine 
the NKA activity of transfected HEK293A cells or untransfected cells as described by Howie 
et al.252. Cells were cultured on 12-well plates until they reached 70% confluency. The 
measurements were performed in presence of the sodium ionophore monensin (Sigma) to 
ensure consistent intracellular Na+ and the Na/K/2Cl cotransporter inhibitor bumetanide 
(Sigma) to depress background uptake of 86Rb. Cells were rinsed with the extracellular 
solution and equilibrated with exactly 1 mL/well of same solution for 20 min at 37°C. During 
change of the medium, we added 100 µM ouabain to half of the wells and PBS (vehicle) to 
the other half and incubated at 37°C for 5 min before initiating 86Rb uptake by the addition of 
1 µCi/mL 86Rb per well. The cells were incubated at 37°C for exactly 15 min previous to 
stopping the uptake by rapidly washing steps in three baths of ice cold PBS. The complete 
wash protocol should take ~30 sec. Hereupon, cells were lysed in 0.2 mL lysis buffer per well 
(1% Triton-100 in PBS). The specific activity of the 86Rb solution is determined through 3x 
measurements of 1 µL 86Rb solution in 3 scintillation vials ('total counts vials'). Next to this, 3x 
50 µL of each cell lysate per well was transferred to 3 separate scintillation vials for. Likewise 
3x 5 µL cell lysate volume to 3x cuvettes containing protein assay reagent. The number of 
86Rb molecules of the lysates were measured in a liquid scintillation counter, and the protein 
content of lysates was measured in a spectrophotometer using a Bradford assay with bovine 
serum albumin as a standard. 
 
Extracellular solution (pH7.4) 
 
20mm NaCl    10mM HEPES 
120mM NMDG-Cl   10 µg/mL monensin 
1mM MgCl2    10mM glucose  







2. 2. 17 Immunofluorescence 
 
Immunofluorescence antibody staining was performed on transduced and nontransduced 
cardiac myocytes to visualize expression, localization and co-localization of single and 
multiple stained proteins. Even though crosslinking agents, like paraformaldehyde, are better 
in preserving cell structure, they reduced the antigenicity of some cell components, which 
was the case in most of our test experiments. For this reason, cells were fixed for 20 min with 
ice-cold 99.9 % ethanol at -20°C to immobilize antigens. Fixed cells were either stored in 
PBS at 4°C or directly blocked with blocking buffer (20% FCS and 0.15% Triton X in PBS) for 
2 h. The cells were washed with PBS and co-stained with rabbit polyclonal anti- FXYD1 
(abcam)  and either mouse monoclonal anti-α1 antibody (Millipore) or goat polyclonal anti-
PDE3A (Santa Cruz) antibodies in in blocking buffer over night at 4°C, washed once with 
PBS, followed by the incubation with secondary antibodies diluted as mentioned in section 2. 
1. 9 for 2h at RT. Confocal imaging was performed using Zeiss LSM 710 laser scanning 
confocal microscope (Carl Zeiss MicroImaging) equipped with a Plan-Apochromat x63/1.40 
oil-immersion objective. 
 
2. 2. 18 Heart failure rat model: Myocardial Infarction  
 
For the animal model used in this project, adult male Sprague Dawley rats (250-300 g) were 
subjected to proximal coronary ligation to induce chronic myocardial infarction as described 
before145. All surgeries and experiments with failing cells were performed at Imperial College 
London (lab of Prof. Julia Gorelik). Briefly, the rats were anesthetized after treatment with 
antibiotics and buprenorphine (0.03 mg/kg).  After an incision into the pleural space of 
the chest, the left anterior descending coronary artery was ligated by a suture with 6-0 silk. 
Sixteen weeks post surgery the MI-rats were subjected to echocardiography analysis via 
Vevo, 770 micro-imaging system, Visualsonics. Upon extraction at 16 weeks post MI, hearts 
and aged matched control (AMC) hearts were weighed. The measured heart weight to tibia 
length ratio (HW/TL) served as an indicator of progressive hypertrophy next to ejection 
fraction volume, which was determined from M-mode of the used imaging system.  
 
2. 2. 19 ARVM Isolation by Langendorff perfusion   
 
The adult rat ventricular myocytes were isolated by Langendorff perfusion by Tobias Goldak, 
(AG Nikolaev, Gö). 
Before the isolation process started, the heart perfusion system was turned on in order to 
warm up the waterbath and its plastic tubing system. At 37°C reached in the water bath 





sacrificed by cervical dislocation. The thorax was cut open,  leaving the atrias easy to 
access. 1 mL of Heparin (25000 I.E./5ml, Rotexmedica) was injected to one of the atrias. 
After reducing the bleeding with some paper tissue, the heart was rapidly excised. After 
washing the heart gently but quickly in 5 mL ice cold 1 x  perfusion buffer, it was transferred 
to a petri dish filled with ice cold 1 x perfusion buffer. The aorta was mounted onto a grooved 
cannula with the help of two tweezers under a stereomicroscope as quickly as possible (not 
more than 2 min), secured with a clip and tied with suture. The heart was perfused with 1 x 
perfusion buffer through the tubing systems (8 mL/min). As soon as the blood was washed 
(as judged by checking the color of the collected perfusion buffer, which went through the 
coronary arteries (1-2 min perfusion)), the solution was switched to the digestion buffer. We 
digested for 11 minutes, whilst collecting the collagenase buffer and recirculating by topping 
up the reservoir until the required time of the digestion is attained. Before the digestion time 
ended, 5 mL of digestion buffer was collected and transferred to a beaker. After 11 minutes 
of digestion the perfusion system was shut down and the ventricles of the heart were 
removed from the cannula into the prepared beaker. The ventricles were cut into small 
pieces to increase the surface area for digestion. The smaller pieces were homogenised via 
a 10 mL pipette mechanically. This procedure was repeated after adding 10 mL of stopping 
buffer into the cell suspension. The suspension was topped up to 25 mL with stopping buffer 
and filtered using a nylon mesh  and left to settle for 8 min and washed twice with 25 mL 
stopping buffer having 8 min settlement time in between each step. 
The sedimented cardiomyocytes were further subjected to re-calcification protocol. 
Intracellular calcium was increased in 3 steps to have a final concentration of 1 mM, letting 
the cells settle for 8 minutes after each step:  
 
25 mL stopping buffer  2.5 µL CaCl2 1 M  final concentration 100µM 
25 mL of stopping buffer 10 µL CaCl2 1 M  final concentration 400 µM 
25 mL of stopping buffer 22.5 µL CaCl2 1M  final concentration 900 µM 
 
Upon recalcification the cardiomyocytes were resuspended in 10 mL M199 medium with 
supplements. Before plating the freshly isolated ARVMs on laminin (Sigma) coated glass 
coverslips, the cells were counted in a counting chamber (Naubauer Chamber) in order to 
calculate the desired amount of cells per well for adenoviral transfection. Cells were 
maintained in culture at 37°C / 5% CO2 for at least 2h prior to use in biochemical/ adenoviral 







10 x Perfusion buffer (substances in mmol/L): 120.4 NaCL, 14.7 KCl, 0.6 KH2PO4, 0.6 
Na2HPO4x2H2O, 1.2 MgSO4x7H2O, 10 Na-HEPES, pH 7.4 in H2O. 
1 x Perfusion buffer (substances in mmol/L): 4.6 NaHCO3, 30 taurine, 10 2,3- 
butanedione-monoxime, 5.5 glucose, 50 mL 1 x perfusion buffer ad 500 mL H2O. 
digestion buffer: straight before use, 50 mL of the perfusion buffer were supplemented with 
40 μM CaCl2 and 0.1 g Collagenase Typ II.  
stopping buffer: 130 mL supplemented with 10 % FCS and 12.5 µM CaCl2. 
culture medium: 500 mL M199 medium (Sigma) was supplemented with 312.5 mg taurine, 
500 mg D,L-Carnitine and 327.5 mg D,L-Creatine, 5 mL antibiotics (100 U/mL penicillin, 100 
µg/mL streptomycin). 
 
Hearts from adult male rats with the induced myocardial infarction model and aged matched 
control rats were isolated as previously described253 by Peter O´Gara at the Imperial College 
London. 
 
2. 2. 20 FRET measurements of ARVMs transduced with PLM-E1 and E1-camps 
 
Cardiomyocytes on laminin coated coverslips underwent a 48 hours incubation upon 
adenovirus transduction and were washed off excessive viral particles once with fresh culture 
medium before starting the FRET experiments. The coverslips with transduced cells on them 
were mounted in the cell chamber, which was used during imaging experiments. Cells were 
washed once and 400 µL fresh FRET buffer was added (300 µL if one was using 3 or more 
substances during experiments). All substances used during FRET experiments were diluted 
in FRET buffer. Using a drop of immersion oil, the chamber was placed onto the objective 
(x63) of the microscope. 
Measurements were performed on an inverted fluorescent microscope and analyzed using 
ImageJ software. The components of a FRET microscope system included a light source to 
excite donor protein at its excitation wavelength, a beam splitter to divide the emission light 
of the donor and acceptor protein into two independent channels, and a camera to detect 
donor and acceptor channel intensities simultaneously (Figure 13). As described before239 a 
CoolLED single-wavelength light emitting diode was used as the light source for all FRET 
experiments. ARVMs with a good sensor expression were quickly selected using live 
fluorescent light mode manually to avoid photobleaching effects. The cyan fluorescent 
protein (CFP), integrated in our FRET biosensors as the donor protein, was excited at 440 
nm. The general emitted light from the cell was split into CFP and YFP emission channels 





















Since viral expression of the biosensor protein inside the single cardiomyocyte vary from 
very strong to very low, sporadically showing perinuclear overexpression, cells with 
homologous fluorescence intensities are chosen for experiments. Perinuclear overexpression 
aggregates were excluded from the region of interest in all measurements. Upon adjusting 
the exposure time between 20-40 ms to have a relatively good signal-to-noise ratio, 
especially at the baseline, the images of the CFP and YFP emission channels were recorded 
every 5 seconds. As soon as a stable baseline had been reached, the compound dilutions at 
a volume of 400 µL (or 300 µL) were gently added and changes of the YFP/CFP FRET ratio 
were monitored. The obtained raw data for CFP and YFP channel intensities were analyzed 
offline using Microsoft Excel and Origin 8.5 software. For precise quantification of the 
changes in intensities during a single measurement, the YFP/CFP intensity ratio was 
corrected for the bleedthrough (0.9 coefficient) of the donor fluorescence into the acceptor 
channel: 
 
FRETratio = (YFPintensity - 0.9 x CFPintensity) / CFPintensity 
 
All data shown in section 3 are corrected FRET ratios calculated from the raw intensity data. 
 
2. 2. 21 Statistics 
 
All data were analyzed using Origin Pro 8.5 software and shown in means ± SE and 
differences between experimental groups were analyzed using the one-way ANOVA test. 
Differences were considered significant at p<0.05. 
 
Figure 13. Layout of the 
FRET imaging setup 
comprised of a CoolLED, 
inverted Nikon microscope, 
DV2 DualView, and ORCA-











3. 1 Generation of the first version of the PLM-E1 FRET Biosensor  
 
In order to measure spatio-temporal regulation of cAMP dynamics in the vicinity of 
Phospholemman (PLM), we developed a FRET based biosensor derived from the cytosolic 
cAMP sensor E1-camps or simply E1-camps249 fused to the carboxyl terminus of the human 
PLM cDNA provided by Prof. Michael Shattock. The cytosolic E1-camps sensor is based on 
a single cAMP binding domain and was used as control in all FRET experiments. The reason 
to use Epac1-camps is its capability previously identified in other studies to show a larger 
FRET change upon cAMP binding in cells, although having a slightly lower affinity than some 
other cAMP sensor such as Epac2-camps (~2 μM vs. ~1 μM)239. 
The humanPLM sequence was fused to the YFP-Epac1-CFP sequence of E1-camps cDNA via 
NheI restriction endonuclease site to create the plasmid PLM-E1 in the pcDNA3.0 vector. 
Additionally, the sequence between PLM and YFP contained a special linker consisting of 18 
bp (encoding GSGSAS), which should ensure a proper folding of the sensor during the 
translation of the protein (Figure 14). 
Hereupon, one had to test the functionality of the targeted cAMP sensor in living cells. 
The pcDNA3.0 vector with its cytomegalovirus enhancer-promoter drives sensor expression 
in mammalian cells and simplifies its expression in HEK 293A cells after transfection with the 



















Figure 14. PLM-E1 construct in pcDNA3.0 vector.  
The vector containing the PLM-E1 coding sequence 
contain a short linker (18 bp) GGA TCC GGA TCT GCT 





























3. 1. 1 Expression and functional analysis 
 
First tests of transiently transfected HEK 293A cells were performed under a fluorescent 
microscope to analyze subcellular localization and to do first experiments of the FRET 
functionality of the targeted sensor. Epifluorescence images of PLM-E1 containing HEK293A 
cells showed a regional sensor expression pattern (Figure 15A), as expected. PLM-E1 
localized at the plasma membrane and exhibited robust FRET. Upon β-adrenergic agonist 
isoproterenol (Iso) mediated cAMP stimulation, the PLM-E1 transfected HEK293A cells 
responded with a change in FRET ratio, proving its functionality in the sensor (Figure 15C).  
SDS Page/Western blotting was carried out to check the size of the expressed protein. 
Based on the generated sequence, the PLM-E1 protein should have a theoretical size of 
approximately 75 kD. Immunoblot analysis of PLM-E1 transfected HEK293 cells under non-
stimulated conditions were performed and investigated regarding relative expression level 
and molecular weight. Using anti-GFP antibodies, we observed bands corresponding to this 
theoretical weight for products expressed from the pcDNA construct including one additional 
band at about 20 kD corresponding to the size of a monomeric GFP (CFP/YFP), indicating a 
possible partial degradation of the sensor protein (Figure 15B). Thus, our results indicate that 























Figure 15. Expression, function and 
localization of PLM-E1 in HEK 293 cells.  
(A) An epifluorescence image of a PLM-E1 
transduced HEK 293A shows a predominant 
location on the plasma membrane, as expected. 
(B) Immunoblot analysis of PLM-E1 protein (~75 
kD) expression after 24 hour transfection of 
increasing plasmid amounts into HEK293 cells 
probed with anti-GFP antibody. Blot is 
representative of at least three individual 
experiments. (C) FRET ratio trace recorded in 
HEK293A cells expressing PLM-E1. Isoprenaline 
(Iso) 100 nM induced an increase in cAMP 
visualized by a decrease in YFP/CFP FRET ratio, 







3. 1. 2 Localization analysis 
 
Since we plan to use the PLM-E1 as a tool to detect cAMP dynamics in the microdomain 
formed by PLM and the Sodium Potassium Pump in adult rat ventricular myocytes (ARVMs), 
it is obligatory to prove the physical association of the newly developed tagged PLM-E1 
FRET biosensor with the α1-subunit (α1-SU) of the NKA, comparable to endogenously 
expressed PLM in ARVMs. Using anti-NKA α1-SU antibodies immobilized on protein G-
Sepharose beads, α1-SU was immunoprecipitated from PLM-E1 transfected HEK 293A cells, 
and all samples taken during the experiment were probed with anti-GFP antibodies. 
Interestingly, we could not detect any signal in the IP fraction (Figure 16A), likely due to the 
fact that although the biosensor is highly membrane localized, the expressed PLM-E1 protein  
is not associated with the α1-subunit. Troubleshooting for this problem led to optimization of 
the PLM-E1 construct with the already published caninePLM-YFP sequence, for which positive 
co-IP with the NKA has been published254.  Of note, it is well known that HEK293 cells do not 
natively express any PLM. Considering this, it is not possible to detect any endogenous PLM 






















No  Sample  
1  Lysate  
2  Supernatant of lysate  
3  Resuspended cell pellet  
4  Supernatant of beads  
5-9  Washing steps  




(higher conc.)  
A B 
C D 
Figure 16. Co-immunoprecipitation by 1 µg α1-SU antibodies immobilized on Sepharose beads with the 
previously established protocol (see Methods) is shown. (A) PLM-E1 could not be immunoprecipitated from 
HEK 293A cells transfected with the PLM-E1 plasmid. (B) 24 h transfection of HEK 293A cells with humanPLM-
YFP and (C) caninePLM-YFP varying in their linker length were used as controls for the co-IP experiments. (D) 
Immunoprecipitation starting material (No 1-3), material not immunoprecipitated (No 4: not IP-ed fraction) and 
immunoprecipitated material (No 5-10+: IP fraction) were separated on SDS-PAGE (10% gel), gels were 
transferred to membranes immunoblotted as shown. The protein folding does influence the association of 
PLM-E1 with the sodium pump α1-subunit.  caninePLM-YFP with a long linker shows a high capacity in binding to 







3. 2 Generation of the optimized PLM-E1 FRET Biosensor and the adenoviral construct 
 
Despite of testing the functionality of the PLM-E1 and the clear change in cAMP induced 
FRET signal responses (Figure 15C) as well as the obvious membrane localization and 
translation of the developed PLM-E1 sensor protein (Figure 15A) , it did not show any 
positive results regarding co-immunoprecipitation with the α1-SU of the NKA (Figure 16A). 
We considered a special caninePLM-YFP cDNA (kindly provided by Dr. William Fuller) as a 
possible alternative for FRET sensor backbone.  
As mentioned in the last section, we also demonstrated that the caninePLM-YFP fusion protein 
construct is clearly associated with the α1-SU of the sodium-potassium pump in HEK 293A 
cells (Figure 16C). It is inserted in a pEYFP N1 vector (Clontech, Paulo Alto, CA) and has a 
long linker sequence (60 bp) KRSRAQASNSAVDGTPVATG between the coding sequence 
for PLM and YFP. 
Upon comparing both PLM-YFP sequences with different linker lengths (18 vs. 60 bp) in co-
IP experiments the caninePLM-YFP was found to built a physical interaction with the α1-SU of 
the NKA (Figure 16B,C). Therefore, this fusion protein was used in all further experiments to 
generate the adenovirus for transfection and FRET analysis of adult rat ventricular myocytes 
(ARVM). 
To produce the recombinant PLM-E1 protein, the yellow fluorescent protein sequence was 
excised from the provided caninePLM-YFP containing pEYFP N1 vector via KpnI (5'end) and 
NotI (3'end) restriction endonuclease sites and ligated via triple-ligation at its C-Terminus 
with the complete YFP sequence amplified from the pEYFP N1 vector through PCR with 
designed primers flanking KpnI and EcoRI sites and the Epac1-CFP sequence digested from 
the Epac1-camps cDNA by EcoRI and NotI to create the plasmid PLM-E1 in the given 
pEYFP N1 vector (Figure 17A). 
As the objective of this project is to characterize β-adrenoreceptor (β-AR) mediated cAMP 
dynamics in the PLM/NKA microdomain in ARVM, we created an adenovirus encoding E1-
PLM using the Invitrogen Gateway® Cloning System. The sensor sequence was amplified 
with specially designed primers containing flanking DNA recombination sequences called BP 
sites. After PCR amplification of an approximately 2255 bp product and gel purification the 
construct was cloned into an entry vector. The PLM-E1 construct was than subcloned into an 
expression vector using the LR Reaction based on DNA recombination. Here, the entry 
vector is combined with the destination vector called pAd_CMV_V5DEST (Figure 17B) and 
further used for amplification in HEK 293A cells. The expression vector contains human 
recombinant deficient (deletion in E3 gene) adenovirus type 5 with a cytomegalovirus 



































3. 2. 1 Sensor characterization - expression 
To investigate molecular weight and the expression pattern of the developed PLM-E1 
sensor, we transfected ARVMs with the PLM-E1 adenoviral construct at a range of MOI 
between 0 and 1000. The lysates were subjected to Western Blot analysis using anti-total 
PLM antibody and anti-GFP antibody. Based on the sequence of the sensor, its theoretical 
molecular weight is expected at 75 kD (Figure 18B). Using the total PLM and the GFP 
antibody we detected a cluster of additional bands at 37 kD and transfection rate dependent 
bands at 50 kD and 22 kD, suggesting gene products originating from unexpected protein 
modification and trafficking in the Golgi apparatus. With regards to sensor expression, we 
examined confocal pictures of ARVMs transfected with the cytosolic E1-camps sensor, used 





Figure 17. Design of the optimized PLM-E1 biosensor construct.  
(A) Schematic representation of the PLM-E1 sensor construct that includes two fluorophores, yellow (YFP) 
and cyan fluorescent proteins (CFP), sandwiching the cAMP-binding domain Epac1 and fused to 
phospholemman (PLM). (B) pEYFP-N1 vector containing the coding sequence for PLM-E1 and showing 
attb forw. and rev. primer binding sequences used for further cloning steps into the final adenoviral vector. 
(C) Map of the recombinant adenoviral vector with the PLM-E1 sequence. It has a truncated version of 
human adenovirus type 5 and a CMV promoter for expression in ARVMs. (D) 1% agarose gel 
demonstrates DNA segments control digestion of the PLM-E1 construct in the pEYFP-N1 vector at ~1900 






tagged version PLM-E1, which should be spatially localized in the PLM/NKA microdomain. 
The genetically modified PLM-E1 sensor expresses the two fluorophores YFP and CFP like 
its predecessor E1-camps, which are recorded in separate detection channels with excitation 

















In the confocal pictures, the PLM-E1 sensor revealed a predominant membrane localization, 
although there were always some aggregates observed in the perinuclear regions which 
could be excluded from analysis of live cell imaging data.  
 
3. 2. 2 Sensor characterization - localization  
 
To insure accurate FRET measurements in the proper compartment of ARVMs, we carried 
out a biotin labelling and purifying procedure of cell surface proteins of PLM-E1 transfected 
ARVMs and saw a clear localization of the biosensor in the surface membrane fraction 
(Figure 19). The sensor was detected with an anti-GFP antibody against the fluorophores 









A1 A2 B 
Figure 18. Expression of the PLM-E1 sensor. (A) Confocal images of AVRMs transfected with adenoviral 
constructs (A1) E1-camps and (A2) PLM-E1. YFP and CFP channels are recorded separately reveal a 
confined Z line dominant pattern for the expression and localization of the targeted PLM-E1 compared to 
Epac1-camps, which is more evenly distributed in the cytosol and membrane parts. (B) Immunoblot 
expression analysis for PLM-E1 transfected ARVM. Cultured ARVMs were transfected for 48 h with the 
adenoviral vectors at 10, 30, 100, 300 or 1000 MOI. Cell lysates were subjected to SDS-PAGE (10% gel) 
and Western blot analysis using an anti-total PLM (1:10000) and anti-GFP (1:160000) antibody. Blots are 
representative of at least three individual experiments. 
 
 
Figure 19. Cell surface biotinylation of PLM-E1 transduced 
ARVM.  PLM-E1 transfected ARVMs were briefly incubated with 
sulfo-NHS-SS-biotin and then incubated for 10 min. Thereafter, cells 
were lysed in 1% triton X-100 in PBS supplemented with protease 
inhibitors (lysis buffer) for 30 min at 4
o
C. Biotinylated proteins that 
had not been degraded (Starting Material, SM) were purified (4 h to 
overnight at 4 °C) using Streptavidin-Sepharose beads (GE 
Healthcare). Upon washes in lysis buffer and collecting the unbound 
fractions (UF), cell surface proteins in the membrane fraction (MF) 
were eluted in SDS-PAGE sample buffer supplemented with 5% (v/v) 
-mercaptoethanol by heating at 60 °C for 10 min. All samples were 



























































To prove the correct localization of the sensor in the PLM/NKA microdomain, confocal 
images of PLM-E1 transfected adult rat ventricular myocytes with a transfection efficiency 
about 80 % (data not shown) were analyzed and revealed a T-tubular pattern and  
sporadically occuring perinuclear regions with enhanced fluorescence intensity (Figure 
18A2). Compared to E1-camps, which is expressed throughout the entire cytosol with 
intense striations at the membrane (Figure 18A1), the PLM-E1 sensor is predominantly 
membrane bound as desired. To visualize the physical interaction of the α1-SU with its 
genetically modified regulatory sensor protein PLM-E1, we immunostained the α1-SU in PLM-
E1 transfected cardiomyocytes. The colocalization analysis demonstrates that there is a 
nearly perfect overlay of the sensor signal (Figure 20B) as well as of the stained endogenous 
PLM (Figure 20A) signal with the α1-SU, indicating that the sensor localization corresponds to 




























With regards to biochemical evidence, co-immunoprecipitation experiments revealed the 
association of PLM-E1 with the α1-subunit in transduced ARVM and thus the correct 
localization of the sensor (Figure 21). 
A B 
Figure 20. Co-localization of PLM-E1 with the sodium pump. Representative confocal images (n ˃ 5 for 
each) of immunostained (A) Wildtype and (C) PLM-E1 transfected (300 MOI) ARVMs. Co-localization of 
PLM with α1-SU of the NKA is confirmed for endogenously expressed PLM and the overexpressed PLM-E1 






For this purpose, we first conducted co-immunoprecipitation experiments with immobilised 
α1-SU antibodies on protein G-Sepharose beads to detect total phospholemman of PLM-E1 
transfdunced ARVM. As expected, the beads catched endogenous phospholemman at 17 kD 
and the expressed the biosensor at 75 kD amongst other PLM including bands, characteristic 
for the sensor protein PLM-E1 (Figure 21A). Equally, we analysed E1-camps transfected 
ARVMs as a negative control, in which case only the endogenous PLM at 17 kD could be 
pulled down from the lysed cells (Figure 21A).   
To insure the association of PLM-E1 with the endogenous NKA-α1-SU, we have additionally 
used the GFP-Trap reagent (Chromotek), which has an excellent binding to fluorescent 
proteins, with no background or non-specific capture. Because the antibody is raised in 
lamas, one gets no interference of heavy and light IgG chains with sodium pump antibodies 
when immunoblotting. Compared to the E1-camps transduced ARVMs as a negative control, 
the α1-SU could be successfully pulled down almost entirely from the unbound fraction (No. 
4) into the IP-fraction (No. 10; 10+) (Figure 21B). We looked further into the co-
immunoprecipitated GFP fractions of the sensor protein and detected a strong GFP band in 
the IP fraction at the expected size of 75 kD. Additional bands at 37 and 22 kD were 
detected, which are characteristic for PLM-E1 expression in cardiomyocytes, as indicated in 

























Figure 21. Association of PLM-E1 with the sodium-potassium pump α1 subunit. 
(A) Representative immunoblots containing α1-NKA+PLM coIP analysis in PLM-E1 and E1-camps transfected 
ARVM. For co-IP of PLM-E1 and the α1-NKA, three wells (~ 90.000 cells) of PLM-E1 and Epac1-camps (neg. 
control) transfected ARVM were used. Myocytes were lysed in 2 mg/ml C12E10 (Sigma) in PBS supplemented 
with protease inhibitor cocktail  (Roche) and PhosStop (Roche) phosphatase inhibitor mixtures, insoluble material 
was removed by centrifugation at 17,500 × g for 5 min at 4 °C. Supernatants were agitated overnight at 4°C with 
anti-NKA-α1-subunit monoclonal C464.6 (Santa Cruz Biotechnology) preimmobilized on protein G-Sepharose 
beads (GE Healthcare). After multiple washes in 0.5 mg/ml C12E10 in PBS, all samples taken during the 
immunoprecipitation procedure were eluted in SDS-PAGE sample buffer, separated by SDS-PAGE (12 % gel), 
transferred to membranes, and immunoblotted for total PLM.  
(B) Representative Western Blots with immunoprecipitation experiments of fluorophores of PLM-E1 and Epac1-
camps transfected ARVM (~ 90.000) precipitated using GFP-Trap (Chromotek) under identical conditions, and 






3. 2. 3 Sensor characterization - function  
 
For functional analysis of the inhibitory effect of the PLM-E1 sensor on NKA, we measured 
the ouabain-sensitive influx of radioactive 86Rb+, thereby monitoring the NKA activity in HEK 
293 cells stably expressing PLM-E1. Stable transfection of HEK293 with the sensor resulted 
in approximately 37 % loss of NKA activity showing a siginificant dicrease in  86Rb+ uptake 
compared to a non-PLM-expressing HEK 293 line (Figure 22), indicating that the expression 
of PLM-E1 inhibits the sodium pump. Hence, sensor protein PLM-E1 is properly inhibiting the 
NKA, as the endogenous PLM does.  
To test the FRET capability of the PLM-E1 sensor, we stimulated transduced ARVMs with 
the β-AR agonist isoproterenol (Iso) and monitored a clear decrease in YFP/CFP ratio as a 
consequence of the local microdomain cAMP increase, thus proving sensor functionality 































































































































Figure 22. Inhibition of NKA activity by 
PLM-E1. Na pump activity was measured as 
ouabain-sensitive 
86
Rb uptake by cells 
stably expressing PLM-E1. In this assay 
pump activity is expressed as a percentage 
of the activity in the same cell line which do 
not express PLM. PLM-E1 expressing 
HEK293 cells inhibit the sodium pump, 
HEK293 do not (n = 3; *P < 0.05) 
 
Figure 23. Sensor function in PLM-E1 
transduced ARVMs. (A) Representative FRET 
signal trace recorded in a PLM-E1 transfected 
myocyte. Treatment with isoprenaline 100 nM 
induces an increase in cAMP and a significant 
decrease in YFP/CFP ratio. (B) Recorded single 
YFP (acceptor) and CFP (donor) intensities for the 
same experiment. (C) Representative region of 
interest for a single FRET experiment in PLM-E1 
transfected ARVM excluding strongly fluorescent 






The next step was to exclude PLM-E1 sensor affinity for cAMP and Isoprenaline sensitivity. 
Transduced cardiomyocytes were treated with the adenylyl cyclase inhibitor MDL12,330A to 
minimize basal intracellular cAMP before performing the concentration-response FRET 
experiments with the cAMP analogue 8-Br-2´-O-Me-cAMP-AM. In addition, the biosensor 
sensitivities were compared between the localized PLM-tagged and the cytosolic sensor in 
terms of FRET response to increasing concentrations of Iso.  
We demonstrated that the membrane localized PLM-E1 sensor has a slightly lower affinity to 
cAMP than the cytosolic E1-camps (EC50= 4.1 ± 1.1 vs. 0.9 ± 0.2 µM, respectively) (Figure 
24A). The concentration response dependency for Iso revealed a comparable sensitivity of 
PLM-E1 with the cytosolic E1-camps (Figure 24B). Hence, the non-tagged biosensor does 
not show a more intense perception of FRET changes in the cytosol than the localized 
sensor meaning that we could expect commensurate results for microdomain and cytosol in 















































































Figure 24. Sensitivity of E1-camps and PLM-E1 to cAMP and increasing isoprenaline (ISO) 
concentrations. (A) Concentration response dependencies measured in PLM-E1 and E1-camps 
transduced ARVMs pretreated with the adenylyl cyclase inhibitor MDL12,330A (100 μM) for 10 minutes 
and treated with increasing concentrations of the cell-permeable cAMP analogue cAMP 8-Br-2’-O-Me-
cAMP-AM. PLM-E1 shows a ~4-times lower affinity for than the cytosolic E1-camps biosensor (EC50= 
4.1 ± 1.1 vs EC50=0.9 ± 0.2 1 µM). Means ± SE, n=7-12 cells from 4-5 rat hearts each. (B) Isoprenaline 
induced FRET response for the Epac1-camps and the PLM-E1 sensor. Accordingly transfected ARVM 
treated with Iso concentrations ranging between 0.001 nM and 1 µM displayed no significant 
differences regarding the sensor Iso sensitivity for the targeted PLM-E1 and cytosolic E1-camps 
sensors EC50 values were 4.4 ± 1.2 and 4.3 ± 0.7 nM, respectively. Means ±n=15 and 10 cells from 4 






























































3. 3 Comparative FRET analysis of E1-camps and PLM-E1 transduced ARVMs 
 
Phospholemman exerts its inhibitory effect on the Na+/K+-ATPase only when it is not 
phosphorylated by kinases, for example at its Ser-68 residue by the PKA, which is 
downstream of the adrenergic β1- or β2-adrenergic receptor subtypes.  
 
3. 3. 1 Effects of individual β-AR subtypes 
 
To investigate which subtype is involved in the receptor-cAMP signaling pathway in the 
PLM/NKA microdomain, we performed the following FRET-based experiments. Individual β-
AR subtypes were selectively stimulated in E1-camps and PLM-E1 transduced ARVMs of 8-
10 weeks old rats. To do so, we inhibited the β1-AR with CGP-20712A (100 nM) and the β2-
AR with ICI 118551 (50 nM) and stimulated the cAMP production with Isoprenaline (100 nM). 
As a result, in the cytosol, we could detect proportionally the same signal strength in β1-AR 
FRET response as in the PLM microdomain. In contrast, we measured a significantly higher 
amount (~ 65 %) of β2-AR-cAMP induced FRET ratio change in the PLM/NKA microdomain 
compared to the cytosol (Figure 25E). β2-AR signals have been previously demonstrated to 
be localized at T-tubular membranes and to be highly locally confined29. This data correlates 
with the displayed expression pattern of PLM-E1 sensor  (Figure 18A2) and its ability to 



































































































3. 3. 2 PDE Profiles in PLM-E1 and E1-camps transduced ARVMs 
 
It is well known, that through local activities of specific phosphodiesterases (PDEs), cAMP in 
the heart is organized in distinct microdomains. To investigate the organization of cAMP 
signal transduction in the PLM/NKA microdomain, we performed a series of experiments to 
analyze the regulation of cAMP dynamics via PDE families in the vicinity of Phospholemman 
versus the cytosol. Since the low availability of the inhibitors for PDE1, 8 and 9 prohibited 
further investigation in terms of their role in modulation of cyclic nucleotide signaling in the 
PLM/NKA microdomain and as the predominant cAMP degrading PDE subtypes in the heart 
are PDE2, 3 and 4, we focused on the latter ones. Looking at basal actions of the 
Phosphodiesterases and their control of local cAMP microdomains, we measured FRET 
responses without β-AR stimulation of ARVM transduced with PLM-E1 and E1-camps. We 
used specific inhibitors for PDE2, 3 and 4 without prestimulating with Iso and continued with 
a general PDE blocker IBMX and further increase the cAMP production,  adding Iso and 
Forskolin (Forsko) as the last steps until we fully saturated the FRET sensor. For 
calculations, we related the data to the maximal stimulation signal of the sensor. 
Interestingly, we detected no significant difference between any PDE family in E1-camps 
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E 
Figure 25. Predominant control of β2-AR over the PLM/NKA microdomain. 
(A,B) Representative FRET traces for E1-camps and PLM-E1 expressing rat cardiomyocytes upon 
β1-AR-selective stimulation (100 nM ISO + 50 nM of the β2-AR blocker ICI 118551). (C,D) 
Representative FRET traces from Epac1-camps and PLM-E1 rat cardiomyocytes after β2-AR-
selective stimulation (100 nM ISO + 100 nM of the β1-AR blocker CGP-20712A). β1-AR stimulation 
showed no significant difference in FRET response between bulk cytosol and the PLM/NKA 
compartment. Maximal stimulation of adenylyl cyclase was achieved by selective PDE inhibitors used 
in different concentrations described in the next section, the unselective PDE inhibitor IBMX (100 μM) 
and the direct adenylyl cyclase activator forskolin (10 µM). (E) Quantification of the FRET 
experiments. Selective β2-AR stimulations strongly rise cAMP the PLM/NKA microdomain and 
resulted a significant difference to the cytosolic FRET response. β1-AR stimulation did not show a 
different percentage in max. FRET responses in the PLM/NKA microdomain compared to bulk 






























































seems to be strongly regulating basal cAMP levels in close proximity of PLM, as compared to 
the general cytosolic level of FRET response. In rat cardiac myocytes, splice variants of the 
PDE2 isoform, especially PDE2A2 and PDE2A3 have been found as preferentially 
associated with functional membrane structures, such as plasma membrane114, which could 

























In the next set of experiments, we focused on the effects of PDE Inhibition in the presence of 
isoproterenol. Under selective stimulation of β1- and β2 -ARs, we analyzed the PDE profiles 
of PDE2, 3 and 4 after subtype specific β- adrenergic stimulation in the microdomain versus 
the cytosol and could not find any differences amongst the groups regarding the β1-subtype 
stimulation (Figure 27C).  Looking at the FRET responses to individual PDE inhibitors after 
β2-AR stimulation, we discovered that cAMP dynamics in the vicinity of the membrane protein 
Phospholemman are predominantly regulated via PDE3 in the PLM/NKA microdomain 
(Figure 27D). The localized PLM-E1 sensor detected an up to two-fold higher FRET signal 


































C Figure 26. Significant PDE2 contribution to basal 
cAMP degradation in the vicinity of PLM. 
Representative FRET traces upon basal PDE2 
Inhibition of Epac1-camps (A) and PLM-E1 (B) 
transduced 16 weeks old ARVM. Upon specific PDE 
inhibition either with BAY 60-7550 for PDE2 (100nM), 
Cilo for PDE3 (10 µM) or Roli for PDE4 (10 µM), 
cAMP accumulation in the cell is achieved through 
inhibition of all PDEs via IBMX (100 µM) and 
continued with maximum stimulation of the cell by Iso 
(100 nM) and Forsk (10 µM) in order to saturate the 
sensor. (C) Quantification of FRET experiments as 
related to the maximum stimulation uncovered PDE2 
as the PDE family crucial for confining the PLM/NKA 
compartment from the bulk cytosol. Means ± SE, n 
cells from N rat hearts per condition is written on the 






inhibitors after selective β2-AR stimulation. The obtained results were precisely calculated as 


























3. 3. 3 ANP/cGMP mediated PDE3 response in the PLM/NKA microdomain 
 
Since there is an indication, that there is a β2-AR mediated cAMP pool controlled by local 
PDE3 activity in the PLM/NKA microdomain, we tested whether the stimulation of the cGMP- 
producing ANP receptors in PLM-E1 transduced ARVMs have any effect on cAMP levels. 
cGMP can activate PDE2 through by an allosteric mechanism. It can also inhibit PDE3, since 
cGMP acts as a competitive inhibitor of the cAMP hydrolysis by this PDE (for cAMP/cGMP 
crosstalk see Introduction, section 1. 1. 3). Indeed, quantification of all experiments (Figure 























































































































Figure 27. PDE3 pool in the vicinity of PLM confines β2-AR mediated cAMP signals to the 
PLM/NKA microdomain. Representative FRET ratio traces demonstrating PDE3 effects in E1-camps 
(A) and PLM-E1 (B) transduced ARVMs after β2-AR stimulation with Iso+CGP. (C, D) Quantifications of 
the PDE Inhibitor signals as a % of the general PDE inhibitor IBMX effect. There is a markedly 
increased response to PDE3 Inhibition after selective β2-AR stimulation in the PLM/NKA compartment 
in contrast to the bulk cytosol. * - significant differences at p<0.05. Shown are means ± SE, n=cells 
from N=rat hearts per condition written on the bars. Substance concentrations: ISO 100 nM, IBMX 100 



























































































(Figure 29A,B), demonstrate that β2-AR-triggered FRET signals could be further decreased 
by the addition of ANP and abolished via Cilo-pretreatment (Figure 29B). PLM and PDE3 
colocalization was analyzed by confocal imaging experiments with cells from 8-10 weeks old 
animals. Thus, freshly isolated ARVM were immunostained with PDE3 and total PLM specific 
antibodies (Figure 28A) to study the degree of the overlay (Figure 28B). Good colocalization 
of PDE3 with the endogenous Phospholemman could be confirmed, which supports the 



























































Figure 28. Co-localization of the PDE3A isoform with the PLM 
microdomain. (A) Representative ARVM immunostained with specific anti-
PLM and anti-PDE3 antibodies (B) showing a high degree of colocalization 
(n˃10).  
 
Figure 29. ANP induced PDE3 inhibition in ARVM 
results in high levels of β2-AR/cAMP in the PLM/NKA 
microdomain. (A) Treatment of PLM-E1 transfected 
ARVM with atrial natriuretic peptide (ANP, 100 nM) after 
selective β2-AR stimulation (Iso+CGP) leads to further  
accumulation of cAMP in the vicinity of PLM, (B) which 
is abrogated by Cilo (10 µM) pretreatment, indicating a 
PDE3-dependent effect.  
(C) Quantification of FRET ratio change to ANP 
treatment of PLM-E1 ARVM shown in % Iso + CGP with 
and without pretreatment with Cilo. * - significant 
differences at p<0.05. Shown are means ± SE, n=cells 








3. 3. 4 FRET measurements in PLM-E1 and E1-camps transfected ARVMs 
 
Considering the important pathological changes in β-AR - cAMP - PKA signaling at the 
subcellular level, we investigated possible alterations of spatiotemporal cAMP regulation in 
the vicinity of Phospholemman in ARVMs isolated from animals after myocardial infarction 
(MI). Sprague-Dawley rats were used to generate the progressive chronic heart failure model 
by ligation of the left anterior descending coronary artery via a suture. 16 weeks after MI 
surgery, heart function was significantly decreased in MI vs. aged matched control (AMC) 
group as measured by echocardiography (Table 6).  
 
 
Table 6. Phenotyping of aged matched control and 16 weeks post MI hearts. The results were calculated 
from M-mode echocardiography recordings (Vevo 770 micro-imaging system, Visualsonics) as a marker of 
alterations in wall contractile functionality. Additionally, the heart weight to tibia length (HW/TL) ratio was 
measured after isolation of the respective hearts as an indicator of progressive hypertrophy. 
 
Parameter 
24 weeks old  aged matched 
control (AMC) 
16 weeks post myocardial 
infarction (MI) 
Value  p N Value  p N 
Ejection fraction [%] 84.3 ± 1.5 -- 3 57.0 ± 5.6 p < 0.05 4 
Heart hypertrophy 
[mg/mm] 29.5 ± 0.5 -- 3 36.8 ± 2.3 p < 0.05 4 
 
 
3. 3. 5 Alterations in local PDE dependent cAMP regulation in the PLM/NKA 
microdomain  
 
We found out that the communication between the β2- AR and the PLM/NKA microdomain is 
predominantly driven by PDE3 in wildtype (WT) 8-12 weeks old Wistar rat hearts (Figure 
27D). For that reason, we tested if this communication is deteriorated during the pathological 
state of myocardial infarction. We isolated cardiac cells from 16 weeks post-MI Sprague 
Dawley rats  as control animals and transduced them with the PLM-E1 and E1-camps 
biosensor adenoviruses. After preblocking of the β1-AR with CGP-20712A, we stimulated 
PLM-E1 transfected MI myocytes with Iso and looked at the different PDE inhibitor 
contributions by relating them to the proportion of IBMX induced FRET signal decrease. We 
demonstrated, that upon β2-AR stimulation, PDE3 hydrolyzing activity is downregulated in the 
PLM/NKA microdomain. Concomitantly, PDE2 activity at the sarcolemmal PLM/NKA domain 
is upregulated (Figure 30F). There was no significant change in PDE contribution in 






















































































































































































































































































Figure 30. Contributions of individual PDEs to cAMP hydrolysis after β2-AR stimulation in AMC and 
MI cardiomyocytes. (A,C) Representative FRET traces from AMC and (B,D) MI cardiomyocytes expressing 
PLM-E1, treated with 100 nM Iso+CGP for β2-AR stimulation and subsequently with PDE2 inhibitor BAY 60-
7550 (Bay, 100 nM) or PDE3 inhibitor cilosamide (Cilo, 10 µM), respectively. (E) Quantification of cytosolic 
(E1-camps) FRET experiments revealed no significant changes  of any PDE contribution after MI. (F) 
Quantification of PLM-E1 specific (PLM-E1) FRET experiments showed a significant increase of PDE2 
contribution in the microdomain of MI cells, while PDE3 response was strongly decreased.  Means ± SE, 




















We checked for possible alterations in β2-AR signal responses (Figure 31). Interestingly, the 
MI cells did no longer show a difference between cytosolic and PLM-E1 microdomain 
characteristic responses to Iso. The experiments revealed alterations regarding β2-subtype 
specific cAMP responses, suggesting that the β2-receptor-microdomain communication is 
seriously impaired in myocardial infarcted hearts. 
 
3. 3. 6 cAMP degrading PDE3 pools in the PLM/NKA microdomain are delocalized in 
the hypertrophied heart 
 
Since we showed that β2-AR/cAMP signals are confined in the PLM/NKA microdomain 
through PDE3 activity, we focused on defining the alterations of this confined signaling in the 
chronic heart failure disease model.  PDE3 dependent subtype specific β2-AR responses 
were dramatically diminished in hypertrophied heart cells compared to FRET responses in 24 
weeks old aged matched control (AMC) rat heart cells (Figure 30F). We demonstrated the 
loss of PDE3 localization in the microdomain by immunostaining cardiomyocytes isolated 
from hearts after myocardial infarction with total PLM and PDE3A subfamily specific 
antibodies (Figure 32). Quantification of confocal images using  the Pearson´s coefficient, 
which is an indicator for the degree of co-localization, uncovered a disturbed localization of 
PDE3 in the microdomain in hypetrophied cells compared to aged matched control myocytes 
(0.85 vs. 0.92) (Figure 32). It was no more locally confined and in comparison to healthy 

















































Figure 31. β2-AR effects in AMC vs. MI cells. 
Comparison of the magnitudes of  Iso (100 nM) 
responses measured with the targeted PLM-E1 and 
cytosolic E1-camps in an experiment performed as 
described in Figure 14. These data suggests a serious 
loss of receptor signal to the microdomain after MI 
regarding β2 adrenoreceptor signals. Means ± SE, 
n=cells from N=rat hearts per condition. * - significant 


















































However, when the same protocol for the ANP FRET experiments (3. 3. 3) were applied 
during our analysis for  MI-ARVM, we could not detect any clear FRET signals, so that it was 
not possible to conclude if there are better or worse ANP responses compared to aged 
matched control cardiomyocytes (data not shown). 
  
Figure 32. Confocal microscopy analysis 
of PDE3 localization. Aged matched 
control and MI cells were immunostained 
with the PDE3 family specific antibody. 
Significant delocalization of locally confined 
PDE3 in hypertrophied cardiomyocytes 
were detected. Means ± SE, n=cells from 
N=rat hearts per condition. * - significant 








4. 1 Challenges in generating novel PLM-E1 FRET biosensors with correct structural 
and functional properties 
 
The orchestrated action of specific subsets of PDEs, AKAPs, PKA subtypes and other 
scaffolding proteins involved in creating a local cAMP signalosome in subcellular 
microdomains has been proposed by numerous studies from different labs (see section 1. 1. 
3). The well-accepted model of cAMP compartmentation can explain the observed different 
physiological events operated by the same second messenger. Alterations in NKA activity 
and PLM expression230,255 are known to be associated with cardiac disease and are probably 
connected with a modification of cAMP/PKA dependent NKA regulation. In order to directly 
monitor cAMP dynamics at the PLM/NKA compartment and their changes in heart failure, the 
PLM-E1 FRET-based biosensor was generated. PLM-E1 is a targeted version of the 
cytosolic Epac1-camps249 (E1-camps) biosensor which carries the full-length PLM sequence 
on its N-terminus. Initially, it was attempted to generate the recombinant DNA encoding for 
the PLM-E1 biosensor by tagging the cAMP sensitive single chain biosensor E1-camps to 
the human PLM via a 18 bp long linker region located between PLM and the YFP moiety 
(Figure 14). 
Before generating the recombinant adenovirus with the PLM-E1 insert, non-viral HEK293 cell 
transfection served as a more 'easy-to-handle' gene delivery method to test functionality and 
localization of the sensor. Consistent with previous observations for the predominantly 
membrane expressed YFP-PLM205,254, the inclusion of the PLM sequence in the E1-camps 
construct showed an expected distribution of the targeted sensor exclusively at the plasma 
membrane (Figure 15A). Furthermore, the PLM-E1 sensor showed a correct expression 
pattern (Figure 15B) upon titration using Western blot with anti-GFP antibodies; the bands 
observed corresponded to the respective molecular weight (74 kD). The additional protein 
structure at 20 kD might have been cleaved off during intracellular trafficking. However, we 
demonstrated that this had no effect on the functionality of the sensor (Figure 15C). The 
PLM-E1 transfected HEK293 cells showed a clear decrease in the FRET response triggered 
by Iso mediated intracellular cAMP elevation. Although the optical and functional results were 
as expected, the localized sensor did not co-immunoprecipitate with the endogenously 
expressed NKA-α-SU (Figure 16A) from HEK293 cells in contrast to positive controls (Figure 
16 B,C). This behavior of the sensor construct did not comply with the requirement for the 
PLM/NKA microdomain specific cAMP measurements. This discrepancy could potentially be 
caused by inaccurate folding of the protein of this size as we used a relatively short linker to 
connect the sequences of PLM and YFP.  The optimized version with a 60 bp linker based 






showed equal expression properties like humanPLM-E1 in HEK293 cells (data not shown). 
According to the cDNA sequence, dog and rat PLM are highly homologous256, so there was 
no concern about the compatibility of canine PLM-E1 FRET sensor in ARVMs. While working 
with titer controlled adenoviral gene delivery systems promises 100% transduction efficiency, 
such in vitro studies require a high quality cardiomyocyte population and successful cell 
isolation and culture257. Using an adenoviral vector to transfer the genetically modified 
biosensor sequence into cardiomyocytes is an efficient method which does not require 
damaging treatments for cells such as electroporation, somewhat similar to transgenic 
animal models154,251,258. This adenovirus mediated gene transfer approach has been used in 
many studies to demonstrate discrete spatial and temporal compartmentalization of cAMP in 
adult cardiac myocytes65,111,155,259-261. A clear advantage of in vitro adenoviral system studies 
is that there is no possibility for adverse effects on cardiac morphology and function, as 
compared to transgenic animals. Additionally, in our experiments the adenoviral transduction 
had no effect on cell viability or morphology of the cultured cells compared to non transfected 
cells. Upon generating the adenoviral vector with PLM-E1 as insert (Figure 17C), it was 
possible to characterize the sensor in ARVMs. It is confirmed in several studies that cardiac 
PLM resides at the surface membrane and its phophosphorylation status plays an important 
role in the regulatory effect on the NKA166,262. Similarly, confocal imaging experiments of 
PLM-E1 transduced ARVMs (Figure 18A2 and Figure 20B) revealed thin parallel striations in 
correspondence of the sarcomeric Z lines where endogenous PLM (end. PLM) is also 
expressed next to the NKA-α1-SU (Figure 20A). Despite of the observations of strongly 
fluorescent perinuclear clustering of the sensor in ARVMs, it could be demonstrated that 
there is enough protein expressed at the cell surface which co-immunoprecipitates with the 
NKA-α1-SU (Figure 21). Detailed sensor expression analysis with the tot. PLM antibody 
revealed bands corresponding to the respective molecular weights of the PLM-E1 sensor 
and end. PLM, indicating that not all of end. PLM was replaced by the sensor (Figure 18B). 
The assessed inhibitory effect of the sensor PLM on the NKA was in agreement with the end. 
PLM action76 (Figure 22). Here, we have used a HEK293 cell line engineered to stably 
express PLM-E1, as experiments with transiently transfected cells may be confounded by 
transfection efficiency. 
After adenoviral gene transfer of the PLM-E1 FRET biosensor into ARVMs, excitation of CFP 
at 436 nm and YFP at 514 nm led to robust fluorescent signals in both channels, proving the 
successful integration of donor and acceptor fluorescent proteins into the adenoviral FRET 
construct (Figure 18A2). Excluding areas of sporadically occurring strongly fluorescent 
perinuclear regions, presumably emerging from adenoviral overexpression and incorrect 
intracellular trafficking of the sensor, PLM-E1 was capable of generating a strong FRET 





similar to the unimolecular cytosolic E1-camps sensor which has been known to have a 
relatively large FRET ratio change and a high signal-to-noise ratio248. The kinetic properties 
of PLM-E1 are comparable to those of the E1-camps sensor (Figure 24), allowing FRET 
measurements with a high dynamic range at saturation (i.e. 100 nM) and subsaturating 
concentrations of Iso, which was particularly suitable for comparative measurements of PDE 
effects in the vicinity of PLM and bulk cytosol. 
 
4. 2 Comparative FRET analysis of healthy ARVMs expressing adenoviral PLM-E1 and 
E1-camps biosensors reveal differentially regulated local β-adrenergic signaling 
 
Molecular mechanisms involving cAMP/PKA actions in the vicinity of PLM are known to be 
highly important in regulating cardiac function170. Especially during β-adrenergic stimulation 
PLM is an indispensable regulator of sodium and indirect calcium efflux190, whose absence 
and changes in regulatory properties may lead to alterations in cardiac function230,255. In this 
part of the study, the successful implementation of the localized FRET-based cAMP sensor 
PLM-E1 for direct monitoring of cAMP dynamics exclusively in sarcolemmal PLM/NKA 
microdomain could be demonstrated. Using this approach, it became possible to 
characterize the highly compartmentalized signals in the vicinity of PLM. 
 
4. 2. 1 Restricted cAMP diffusion to the NKA/PLM complex via basal activity of 
phosphodiesterases 
 
It was observed that in PLM-E1 transduced ARVMs without concomitant cAMP stimulation, 
inhibition of PDE2 significantly raises cAMP as detected by the cAMP sensitive locally 
expressed biosensor (Figure 26C). Although the overall PDE2 action in cardiac myocytes is 
small compared to PDE3 and PDE4 activities65, its contribution in cAMP degradation in the 
vicinity of PLM might be of great importance. This almost three-fold higher local PDE2 
responses compared to FRET changes monitored by the cytosolic E1-camps sensor is the 
first direct evidence of PDE2 confining the PLM microdomain from the bulk cytosol. The 
basal PDE2 action in the PLM microdomain may serve to protect PLM in the subcellular 
compartment from excessive phosphorylation. All three PDE2 splice variants have been 
characterized to be located either at the cytosolic or at membrane fractions of cardiac 
myocytes. At the plasma membrane, there is a predominant control of PDE2A2 and PDE2A3 
isoenzyme activities where it can hydrolyze both cAMP and cGMP and regulate the second 
messengers in a compartment-specific manner91. Indeed, it was shown that PDE2 is involved 
in cGMP dependent cAMP regulation of LTCCs of frog ventricular myocytes and human atrial 
cardiac myocytes91,263,264. PDE2 controlled cAMP might play a role in PLM phosphorylation 





It is noteworthy that PDE2 enzyme activity is stimulated by cGMP (as mentioned in chapter 
1. 1. 3). Whether cGMP-mediated, PDE2-dependent decrease of basal cAMP blunts PLM 
phosphorylation and NKA activity remains to be defined. There is still a debate if cGMP is 
involved in PLM phosphorylation219,265. Madhani et al. have reported that the PLM-Ser69 
phosphorylation could contribute to sildenafil (PDE5 inhibitor) induced cardioprotection 
against reperfusion injury via a NO/cGMP dependent pathway. Interestingly, experiments in 
field stimulated cardiomyocytes with an increase in endogenous NO levels revealed PLM 
phosphorylation and increasing NKA activity to be independent of the cGMP/sGC/PKG 
pathway. 
PLM is described to be functionally quiescent in terms of regulating intracellular Ca2+ and Na+ 
levels170, and hence cardiac contractility at basal state. Rather it is recognized as a cardiac 
stress protein under conditions of fight-or-flight response, when it enhances NKA activity to 
minimize the risk of arrhythmogenesis but inhibits NCX to preserve inotropy during stress173. 
Nevertheless, our experiments regarding the control of PDEs over basal cAMP in the vicinity 
of PLM uncovered a possible role of PDE2 cAMP hydrolysis under normal physiological 
conditions. Indeed, further experiments are required to quantify PDE2 regulated NKA activity 
and PDE2 dependent basal phosphorylation rate of PLM for a complete awareness of the 
physiological regulation of NKA with potentially PDE2 modulated PKA targeting of PLM. 
 
Several studies reported the prominent role of PDE4 in cAMP compartmentation in proximity 
to Ca2+ handling proteins important for cardiac contraction. PDE4 isoforms PDE4B and 
PDE4D regulate cardiac contractility and Ca2+ cycling106, furthermore, PDE4D3  was reported 
to act on PKA-mediated RyR2 phosphorylation108. Our findings suggest a trend towards an 
elevated basal PDE4 inhibition effect on the PLM associated cAMP levels but this was found 
to be not statistically different. 
 
4. 2. 2 Locally confined β2-AR mediates cAMP signaling pathway proximal to the 
PLM/NKA complex 
 
It is well known that β1-AR induce far-reaching cAMP signals, whereas β2-AR signals remain 
locally confined28. Indeed, we found that β1-AR responses in PLM-E1 transduced ARVMs to 
Iso induced stimulation were similar to signals detected in the bulk cytosol (Figure 16C). 
Likewise, PDE-dependent regulation of these signals in the microdomain was not 
significantly different from cytosolic β1-AR cAMP signals which is in line with the far-reaching 
control of β1-ARs. In contrast, highly compartment specific β2-AR signals led to greater cAMP 
dependent signal change in the PLM/NKA complex. There is an experimental evidence that 
Cav3 selectively modulates the localization of β2-AR and spatially compartmentalizes its 





compartmentalized by its β-SU in Cav3 rich domains266, also suggested by previous 
observations in co-immunostainings of the NKA-α-SU organized within cardiac caveolin-rich 
microdomains267. Based on our findings, it can be reasoned that β2-ARs phosphorylate PLM 
and build a local signalosome, which might also contain NKA and NCX in close proximity 
(see chapter 1. 2. 1). The signal transduction to the PLM/NKA complex is tightly coupled to 
the regulation of intracellular Ca2+ and cardiac contractility268. Furthermore, Mohler et al. 
report that NKA, NCX1, and InsP3R are complexed with ankyrin-B, an adapter protein within 
a microdomain of cardiomyocyte T-tubules75. This subcelllular complex is demonstrated as 
an essential requirement for Ca2+ homeostasis and proper cardiac function. This is consistent 
with our assumption that β2-AR signals, which originate in T-tubules, reach the PLM 
compartment having an impact on Na+ and Ca2+ cycling in cardiomyocytes.  
As many previous publications269, this study used cultivated cardiomyocytes expressing 
cytosolic and targeted FRET biosensors introduced by adenoviruses, which might cause 
some structural remodeling on t-tubular level270. Despite application of the adenoviral system 
onto control cells transduced with cytosolic E1-camps, there was still the risk in losing the 
proper structure of important cAMP compartments in the complex intracellular architecture of 
cardiomyocytes during cultivation. However, recent studies using morphological analysis of 
cell membrane morphology in rat myocytes after 48 h of adenoviral transduction in culture 
under similar conditions could demonstrate the well-preserved integrity of sarcolemmal T-
tubules29. These morphological findings are supported by our experiments. Obtaining clearly 
distinct results for locally confined β2-AR signals in the microdomain formed by PLM, we 
could confirm different organization of cytosolic and local signaling complex at the subcellular 
level.  
 
4. 2. 3 Critical PDE3-dependent regulation of β2-AR mediated cAMP in the vicinity of 
PLM 
 
Next to their differential coupling to Gs and Gi proteins, the β-ARs differ in subtype specific 
cAMP signaling pathways and phosphorylation of substrates by local pools of PKA. This 
phenomenon is justified mainly through compartmentation of signaling events, such as the 
formation of signalosomes by AKAPs and PDEs (see chapter 1. 1. 2). Nikolaev et al. 
demonstrated that β1-AR-mediated cytoplasmic cAMP is mainly controlled by PDE4, whereas 
cAMP produced after β2-AR stimulation is under the control of multiple PDE isoforms
28. β2-
ARs have a number of interacting proteins including different isoforms of PDE4D, whereas 
PDE4D8 has been shown to be associated with β1-ARs
271. Recently, it was demonstrated 
that membrane localized β2-AR associated microdomains in caveolin-rich membrane 
compartments are primarily modulated by PDE3251. Similarly, in our FRET experiments we 





cardiomyocytes by inhibiting PDE3 (Figure 30F). PDE3 and PDE4 show equal contributions 
to the control of β2-AR mediated cAMP signals in the cytosol (Figure 14D). Since the PLM-E1 
biosensor can relatively well resolve β2-signals in the microdomain (Figure12), it revealed the 
strong cAMP augmenting effect of PDE3 selective inhibitor cilostamide. This clearly 
suggested a strong PDE3 contribution in the signaling effect of β2-cAMP directly at the site of 
the PLM/NKA complex. Preventing cAMP diffusion from β2-AR into the cytosol, PDE3 might 
act as a scaffolding enzyme to localize generated cAMP to the PLM compartment with its 
downstream targets, such as PKA. Even though some groups characterized β2-ARs signals 
to be in tight control of PDE4D isoenzymes possibly organized by arrestins110,272, we and 
others251 have proven that PDE3 might also play a significant role in β2-AR associated 
microdomains, such as the PLM/NKA complex. Experiments demonstrate that cGMP 
inhibited PDE3 provides a sustained increase in cAMP under ANP stimulation, which can be 
abolished by pretreatment with the PDE3 selective inhibitor cilostamide (Figure 29). Physical 
proof of microdomain specific PDE3 activity was provided by co-localization analysis with co-
immunostained freshly isolated WT-ARVMs. Here PDE3 showed a high co-localization with 
end. PLM (Figure 28). It is intriguing to argue that PDE3 is primarily responsible for the local 
modulation of PKA phosphorylation of PLM via β2-ARs. Indeed, through previous work it was 
shown that PDE3 isoenzymes work as scaffolding proteins in spatially confined 
microdomains. For example, PDE3A localizes at the SERCA2 and SR-membrane whereby it 
tightly controls basal cardiac contractility by regulating cAMP mediated phosphorylation of 
PLB and sarcoplasmatic Ca2+ uptake through the SERCA2273. As PDE3 is recognized to 
have a largely interacting role in cardiac Ca2+ cycling and serves as a clinical cardiotonic 
target to regulate β-AR inotropic responses in the heart274,275, it is likely that its 
compartmentalized regulation of PLM under neurohormonal stimulation of β2-ARs is coupled 
to Ca2+-regulatory proteins residing in the same cardiac microdomain, i.e. the NCX.  
The important finding in this work is the predominant activity of the PDE3 enzyme in the β2-
AR-cAMP pool in the vicinity of PLM, where cGMP can act here as a competitive inhibitor of 
PDE3 (Figure 16C). For that reason functional NO-GC activity and effective cGMP synthesis 
might be essential within this microdomain, which in turn appears to be myocyte and species 
specific in previous findings276. In case of the L-Type Ca2+ current, it was shown that its 
regulation via cGMP dependent PDE2/3 vary in different species and source of 
myocytes263,277. Similar conditions prevailed in FRET experiments with aged matched control 
(AMC) animals used in this Ph.D. thesis, which in contrast did not reveal dominant PDE3 
control over β2-AR, rather generally comparable PDE profiles with the PLM microdomain 
were detected. The discrepancy between our findings in 8-12 weeks old Wistar rats and 24 
weeks old Sprague Dawley aged matched control (AMC) animals regarding PDE responses 





difference or this could be another example of local cGMP dependent PDE2/PDE3 crosstalk. 
Despite being not significantly different (p=0.13), there is indeed a clear trend of local PDE2 
to respond to selective inhibition upon β2-AR stimulation in Sprague Dawley AMC animals. 
So there is an appreciated level of potentially cGMP activated PDE2 pool in the β2-AR 
controlled PLM microdomain in 24 weeks old rats. In this regard, further experiments in these 
animals are necessary, which could better explain the moderate FRET change in local PDE3 
response compared to Wistar rats (i.e. different NO-GC-cGMP levels, age related and race 
dependent differences in cardiac physiology, differences of genetic background).  
In conclusion, one could postulate that there is a locally confined cAMP effect on PLM 
regulated by potentially cGMP dependent PDE3, which specifically hydrolyzes the local pool 
of β2-AR-cAMP thereby forming a microdomain and disabling diffusion of the second 
messenger into the cytosol. In addition to its effects on the NKA and NCX (see chapter 1. 2. 
1) there is a possibility that in cardiomyocytes, PLM might potentially be involved in the 
kinetics of LTCCs207. Under these conditions our findings about the role PDE3 in the PLM-
NKA microdomain might have a higher complexity in terms of cardiac contractility. As stated 
above, PDE3 inhibiting cardiotonic compounds are used in the clinic and could also induce a 
local increase in β2-cAMP and subsequent PKA phosphorylation of PLM resulting in higher 
sodium and calcium efflux. The enhanced lusitropic effects would protect from Na+ and Ca2+ 
overload in hypertrophied hearts and limit risks associated with NKA inhibition by cardiac 
glycosides, such as triggered arrhythmias.  
 
4. 3. Alterations of β2-AR control over subsarcolemmal PLM microdomain through 
localized PDE2/PDE3 subsets in ARVM with chronic heart failure 
 
FRET measurements in ARVMs from animals 16 weeks after myocardial infarction showed 
that the significant differences in β2-AR stimulation between the bulk cytosol and the 
PLM/NKA microdomain were abolished (Figure 31 and Figure 32). This loss of 
communication between β2-AR and the PLM microdomain is in line with pathophysiological 
changes occurring during transitioning from early cardiac disease to the functionally 
decompensated state of the heart, which comes along with structural deformation of 
subcellular systems and global as well as local alterations in signaling complexes important 
for proper cardiac function (Figure 5C). Especially, alterations in PDE effects are recognized 
in hypertrophied cells. Increasing body of evidence demonstrate a clear increase in whole 
cell PDE2 activity at end stage of heart failure155,278 protecting the diseased heart from stress, 
which is caused by excessive catecholamine dumping at this state. Also in early stage of HF, 
it was shown that locally detected PDE2 effects at the β2-AR were changed, while whole cell 
PDE2 amounts and activities remained stable251. This microdomain specific replacement of 





mechanism to increased ANP/cGMP effects in hypertrophy. Similarly, our FRET experiments 
in PLM-E1 transduced MI cardiomyocytes revealed a significant decrease of PDE3 response 
after β2-AR stimulation whereas PDE2 contributions increased in the PLM/NKA microdomain. 
Likewise, PDE3 and PLM co-immunostained MI cells showed a significantly decreased co-
localization pattern compared to AMC cells (Figure 32). Interestingly, after β2-AR stimulation 
no differences between AMC and MI cells in PDE contributions to cAMP hydrolysis in the 
bulk cytosol were detected. This might indicate that there is no change in global PDE activity 
after congestive heart failure in ARVMs, but rather subcellular alterations in PDE catalytic 
activity. Previously, it was shown that in rat hearts post-MI, the NKA expression and activity 
were depressed, although the determined overexpression of PLM in MI cells may also 
account for reduced NKA activity173 and altered cardiac contractility279. In addition to previous 
findings, we detected a change in local β2-AR signals in MI myocytes and a decrease in 
PDE3 controlled β2-cAMP in the PLM microdomain being substituted by an increasing PDE2 
effect. Our findings suggest impaired local signaling in the β2-PLM-NKA network which may 
contribute to contractile and electrical dysfunction in arrhythmia upon ischemic disease. 
Since the implemented disease model for this Ph.D. thesis is an example of decompensated 
hypertrophy and chronic heart failure, further investigations about sarcolemmal architecture, 
altered β-AR densities and PLM localized changes of PDE effects on β1-AR-cAMP would 
serve for a more detailed characterization of adrenergic signaling cascade between the 






5. Conclusion and Outlook 
 
The PLM/NKA complex provides the only significant cardiac Na+ efflux pathway and is 
therefore vital for normal physiological function and an important target for therapy during 
congestive heart failure. The aim of this thesis was to extensively study real time dynamics of 
cAMP in the PLM-associated microdomain controlled by β-adrenergic signaling and its 
alterations in chronic heart disease. In order to determine differential regulation of the PLM 
microdomain via subtype specific β-AR signaling and changes of PDE effects over local 
pools of cAMP, a new localized FRET based cAMP sensitive biosensor named PLM-E1 was 
successfully generated und characterized. For the FRET based experiments an adenoviral 
system was used, which enabled titer controlled measurements in transduced 
cardiomyocytes after 48 h cultivation. The present study confirmed the existence of a 
differentially regulated PLM/NKA compartment confined from the cytosolic domain through 
individual PDE subtype contributions to the cAMP degradation under selective stimulation of 
β-AR subtypes. It identified a PDE2 dependent local cAMP regulation in the vicinity of PLM 
(Figure 33), which could be further explored in subsequent biochemical or 
electrophysiological studies, giving insights about PDE2 controlled PLM phosphorylation and 
NKA function or both. The second essential finding is that there is a tight coupling of β2-AR 
signals to the PLM/NKA complex regulated by a specific PDE pattern, which is changed 
dramatically in post-infarcted failing cardiomyocytes (Figure 34). We provided some 
interesting insights but in terms of PDE regulated cAMP/PKA signaling to PLM it would be 
exciting to investigate sodium and calcium induced local changes in cAMP at the plasma 
membrane. Considering its importance in cardiac ECC and the complex role of PLM 
controlling NKA, NCX or LTCCs207 by having three different substrate residues for PKA and 
PKC, it would be intriguing to investigate kinase activities and cGMP dynamics via PKC and 
cGMP sensitive FRET based localized biosensors. 
In the longer term, our observations of PDE-dependent cAMP dynamics at the PLM/NKA 
complex and their changes in heart failure may serve not only as a basis for further studies 
but may also be interesting for clinical treatment of impaired NKA activity leading to sodium 
and calcium overload. Particularly, selective targeting of PDE2 could be a therapeutic 
approach during cardiac arrhythmia or increased catecholaminergic stress which may lead to 






Figure 34. Cartoon demonstrating the change in local cAMP dynamics at the cardiac PLM 
microdomain. In healthy ARVMs there is a privileged communication between β2-AR and PLM/NKA 
microdomain, which is altered in chronic heart failure. This includes the general decrease in the β2-AR 















































Figure 33. Cartoon showing highly confined basal cAMP dynamics and a distinct β2-cAMP 
effect in the PLM microdomain of ARVMs. There is a predominant PDE2 control of the basal cAMP 
pool in the vicinity of PLM, whilst the microdomain specific PDE activities under β1-AR stimulation are 
comparable to those in the cytosol (PDE4˃PDE3˃˃PDE2).  Far reaching β1-AR signals equally effect 
the PLM/NKA complex. The β2-AR mediated cAMP effects on PLM are mainly controlled via cGMP 
dependent PDE3, while the low cytosolic cAMP amounts are hydrolyzed uniformly by PDE2-4. The 
cAMP/PKA regulation of the β2-AR associated PLM/NKA complex strongly rely on PDE enzymes 
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